COMPOUNDS AND USES THEREOF

Description

Background

[0001] An incomplete understanding of the molecular perturbations that cause disease, as well as a limited arsenal of robust model systems, has contributed to a failure to generate successful disease-modifying therapies against common and progressive neurological disorders, such as Parkinson's Disease (PD) and Alzheimer's Disease (AD). Progress is being made on many fronts to find agents that can arrest the progress of these disorders. However, the present therapies for most, if not all, of these diseases provide very little relief. Accordingly, a need exists to develop therapies that can alter the course of neurodegenerative diseases. More generally, a need exists for better methods and compositions for the treatment of neurodegenerative diseases in order to improve the quality of the lives of those afflicted by such diseases.Summary of the Invention

[0002] In an aspect, the present invention provides a compound having the structure of Formula Ic: as defined in the appended claims, or a pharmaceutically acceptable salt thereof.

[0003] In an aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0004] In an aspect, the present invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, for use in therapy.

[0005] In an aspect, the present invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, for use in the treatment of a neurological disorder.

[0006] In an aspect, the present invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, for use in the inhibition of toxicity in a cell related to a protein, in particular toxicity related to α-synuclein or toxicity related to ApoE4.

[0007] In an aspect, the present invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, for use in the treatment of a stearoyl-CoA desaturase (SCD)-associated disorder, in particular a SCD5-associated disorder.

[0008] In an aspect, the present invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, for use in the inhibition of SCD5 or SCD1.

[0009] Any compounds described herein not falling within the scope of the appended claims are included for reference.

[0010] For example, this disclosure features a compound having the structure of Formula I: where R 1< is optionally substituted C 1 -C 6 alkyl, optionally substituted C 6 -C 10 aryl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 2 -C 9 heteroaryl, or optionally substituted C 2 -C 9 heterocyclyl; L 1< is optionally substituted C 1 -C 6 alkylene, optionally substituted C 1 -C 6 heteroalkylene, optionally substituted C 2 -C 6 alkenylene, optionally substituted C 2 -C 6 alkynylene, optionally substituted C 3 -C 6 carbocyclylene, R a< is H or optionally substituted C 1 -C 6 alkyl; L 3< is optionally substituted C 2 -C 9 heterocyclylene; each of X 1< , X 2< , X 3< , and X 4< is, independently, N or CH; L 2< is optionally substituted C 1 -C 6 alkylene or optionally substituted C 1 -C 6 heteroalkylene; and R 2< is optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 2 -C 9 heterocyclyl, optionally substituted C 6 -C 10 aryl, or optionally substituted C 2 -C 9 heteroaryl, or a pharmaceutically acceptable salt thereof.

[0011] In some embodiments, L 1< is optionally substituted C 1 -C 6 alkylene, optionally substituted C 1 -C 6 heteroalkylene, optionally substituted C 2 -C 6 alkenylene, optionally substituted C 2 -C 6 alkynylene, optionally substituted C 3 -C 6 carbocyclylene,

[0012] In some embodiments, L 1< is optionally substituted C 1 -C 6 alkylene, optionally substituted C 2 -C 6 alkenylene, or optionally substituted C 2 -C 6 alkynylene.

[0013] In some embodiments, L 1< is In some embodiments, L 1< is or In some embodiments, L 1< is

[0014] In some embodiments, L 1< is optionally substituted C 3 -C 6 carbocyclylene.

[0015] In some embodiments, L 1< is In some embodiments, L 1< is

[0016] In some embodiments, L 1< is In some embodiments, L 1< is In some embodiments, L 1< is

[0017] In some embodiments, L 1< is In some embodiments, L 1< is

[0018] In some embodiments, L 1< is optionally substituted C 1 -C 6 heteroalkylene.

[0019] In some embodiments, L 1< is In some embodiments, L 1< is In some embodiments, L 1< is

[0020] In some embodiments, R 2< where e is 0, 1, or 2; W is CH or N; Y is NR Y1< ; R Y1< is H, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 10 carbocyclyl, or optionally substituted C 2 -C 9 heterocyclyl; Z is O; and each R 11< is, independently, F, Cl, Br, I, CN, or

[0021] In some embodiments, W is CH. In some embodiments, W is N.

[0022] In some embodiments, R 2< is or

[0023] In some embodiments, e is 0 or 1. In some embodiments, e is 0. In some embodiments, e is 1.

[0024] In some embodiments, R 2< is

[0025] In some embodiments, R 2< is

[0026] In some embodiments, R 2< is

[0027] In some embodiments, R 2<

[0028] In some embodiments, R 1< is

[0029] In some embodiments, R 1< is phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-di-fluoro-phenyl, 3,4-dichloro-phenyl, 3,5-di-fluoro-phenyl, 3,5-dichloro-phenyl, 3-chloro-4-fluoro-phenyl, 4-chloro-3-fluoro-phenyl, 3-chloro-4-nitrile-phenyl, 3-nitrile-4-fluoro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 3-bromo-phenyl, 3-cyclopropyl-phenyl, 3-cyano-5-fluoro-phenyl, 3-chloro-5-fluoro-phenyl, 3-chloro-5-cyano-phenyl, 3-chloro-5-methoxy-phenyl, or 1,3-dihydroisobenzofuran.

[0030] This disclosure features a compound, or pharmaceutically acceptable salt thereof, having the structure of any one of compounds in Table 1 and Table 2 is described herein. In some embodiments, the compound is any one of compounds in Table 1. In some embodiments, the compound is any one of compounds in Table 2.

[0031] As used herein, "CMPD" refers to "compound." Table 1. Compounds of the Invention.CMPD No. Structure CMPD No. Structure 240 248 251 256 258 262 25 263 264 266 272 35 273 36 37 39 40 42 280 43 44 282 45 46 47 48 286 287 50 53 291 55 59 60 298 62 300 63 301 64 302 303 66 304 67 68 69 70 71 72 73 74 75 76 77 80 81 82 83 84 85 328 329 330 331 332 335 342 108 349 117 360 361 127 365 128 367 140 171 172 173 411 174 421 425 427 441 452 Table 2. Compounds of the Invention. CMPD No. Structure CMPD No. Structure 582 583 480 584 590 596 599 600 609 610 618 515 620 623 624 626 523 524 531 532 533 647 546 547 548 652 653 550 658 664 667 564 670 671 672 673 676 679

[0032] This disclosure features a pharmaceutical composition comprising a compound of any of the foregoing compounds, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0033] In some embodiments, the pharmaceutical composition includes a compound of Formula I and a pharmaceutically acceptable excipient.

[0034] This disclosure features compounds or a pharmaceutical composition thereof for use in a method of treating a neurological disorder in a subject in need thereof, the method comprising administering an effective amount of said compounds or a pharmaceutical composition thereof wherein the compounds are any of the foregoing compounds.

[0035] This disclosure features compounds or a pharmaceutical composition thereof for use in a method of inhibiting toxicity in a cell related to a protein, the method comprising administering an effective amount of compounds or a pharmaceutical composition thereof wherein the compounds are any of the foregoing compounds.

[0036] In some embodiments, the toxicity is α-synuclein-related toxicity. In some embodiments, the toxicity is ApoE4-related toxicity.

[0037] In some embodiments, the cell is a mammalian neural cell.

[0038] This disclosure features a compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof for use in a method of treating a stearoyl-CoA desaturase (SCD)-associated disorder in a subject in need thereof, the method comprising administering an effective amount of compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof wherein the compounds are any of the foregoing compounds, or pharmaceutically acceptable salts thereof.

[0039] Non-limiting exemplary SCD-associated disorders include, but are not limited to metabolic disorders (e.g., diabetes (e.g., Type I diabetes and Type II diabetes), hyperglycemia, metabolic syndrome, obesity, lipid disorders, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and hypertension), cancer, cardiovascular diseases, cerebrovascular diseases, kidney diseases, liver diseases, skin disorders (e.g., acne (e.g., acne vulgaris)), central nervous system (CNS) disorders, dementia, multiple sclerosis, schizophrenia, mild cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, and dementia associated with Down Syndrome.

[0040] In some embodiments, the SCD-associated disorder is a SCD1-associated disorder.

[0041] In some embodiments, the SCD-associated disorder is a SCD5-associated disorder.

[0042] This disclosure features compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof for use in a a method of inhibiting SCD5, the method comprising contacting a cell with an effective amount of compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof wherein the compounds are any of the foregoing compounds, or pharmaceutically acceptable salts thereof.

[0043] This disclosure features compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof for use in a a method of inhibiting SCD1, the method comprising contacting a cell with an effective amount of compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof wherein the compounds are any of the foregoing compounds, or pharmaceutically acceptable salts thereof.Chemical Terms

[0044] It is to be understood that the terminology employed herein is for the purpose of describing particular embodiments and is not intended to be limiting.

[0045] Those skilled in the art will appreciate that certain compounds described herein can exist in one or more different isomeric (e.g., stereoisomers, geometric isomers, tautomers) and / or isotopic (e.g., in which one or more atoms has been substituted with a different isotope of the atom, such as hydrogen substituted for deuterium) forms. Unless otherwise indicated or clear from context, a depicted structure can be understood to represent any such isomeric or isotopic form, individually or in combination.

[0046] In some embodiments, one or more compounds depicted herein may exist in different tautomeric forms. As will be clear from context, unless explicitly excluded, references to such compounds encompass all such tautomeric forms. In some embodiments, tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton. In certain embodiments, a tautomeric formmay be a prototropic tautomer, which is an isomeric protonation states having the same empirical formula and total charge as a reference form. Examples of moieties with prototropic tautomeric forms are ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. In some embodiments, tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. In certain embodiments, tautomeric forms result from acetal interconversion, e.g., the interconversion illustrated in the scheme below:

[0047] Those skilled in the art will appreciate that, in some embodiments, isotopes of compounds described herein may be prepared and / or utilized in accordance with the present invention. "Isotopes" refers to atoms having the same atomic number but different mass numbers resulting from a different number of neutrons in the nuclei. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, an isotopic substitution (e.g., substitution of hydrogen with deuterium) may alter the physiciochemical properties of the molecules, such as metabolism and / or the rate of racemization of a chiral center.

[0048] As is known in the art, many chemical entities (in particular many organic molecules and / or many small molecules) can adopt a variety of different solid forms such as, for example, amorphous forms and / or crystalline forms (e.g., polymorphs, hydrates, solvates, etc). In some embodiments, such entities may be utilized in any form, including in any solid form. In some embodiments, such entities are utilized in a particular form, for example in a particular solid form.

[0049] In some embodiments, compounds described and / or depicted herein may be provided and / or utilized in salt form.

[0050] In certain embodiments, compounds described and / or depicted herein may be provided and / or utilized in hydrate or solvate form.

[0051] At various places in the present specification, substituents of compounds of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure include each and every individual subcombination of the members of such groups and ranges. For example, the term "C 1 -C 6 alkyl" is specifically intended to individually disclose methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, and C 6 alkyl. Furthermore, where a compound includes a plurality of positions at which substitutes are disclosed in groups or in ranges, unless otherwise indicated, the present disclosure is intended to cover individual compounds and groups of compounds (e.g., genera and subgenera) containing each and every individual subcombination of members at each position.

[0052] Herein a phrase of the form "optionally substituted X" (e.g., optionally substituted alkyl) is intended to be equivalent to "X, wherein X is optionally substituted" (e.g., "alkyl, wherein said alkyl is optionally substituted"). It is not intended to mean that the feature "X" (e.g. alkyl) per se is optional.

[0053] The term "acyl," as used herein, represents a hydrogen or an alkyl group, as defined herein that is attached to a parent molecular group through a carbonyl group, as defined herein, and is exemplified by formyl (i.e., a carboxyaldehyde group), acetyl, trifluoroacetyl, propionyl, and butanoyl. Exemplary unsubstituted acyl groups include from 1 to 6, from 1 to 11, or from 1 to 21 carbons.

[0054] The term "alkyl," as used herein, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms). An alkylene is a divalent alkyl group.

[0055] The term "alkenyl," as used herein, alone or in combination with other groups, refers to a straight-chain or branched hydrocarbon residue having a carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms).

[0056] The term "alkynyl," as used herein, alone or in combination with other groups, refers to a straight-chain or branched hydrocarbon residue having a carbon-carbon triple bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms).

[0057] The term "amino," as used herein, represents -N(R N1< ) 2 , wherein each R N1< is, independently, H, OH, NO 2 , N(R N2< ) 2 , SO 2 OR N2< , SO 2 R N2< , SOR N2< , an N-protecting group, alkyl, alkoxy, aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), wherein each of these recited R N1< groups can be optionally substituted; or two R N1< combine to form an alkylene or heteroalkylene, and wherein each R N2< is, independently, H, alkyl, or aryl. The amino groups of the invention can be an unsubstituted amino (i.e., -NH 2 ) or a substituted amino (i.e., -N(R N1< ) 2 ).

[0058] The term "aryl," as used herein, refers to an aromatic mono- or polycarbocyclic radical of 6 to 12 carbon atoms having at least one aromatic ring. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, indanyl, and 1H-indenyl.

[0059] The term "arylalkyl," as used herein, represents an alkyl group substituted with an aryl group. Exemplary unsubstituted arylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C 1 -C 6 alkyl C 6-10 aryl, C 1 -C 10 alkyl C 6 - 10 aryl, or C 1 -C 20 alkyl C 6 - 10 aryl), such as, benzyl and phenethyl. In some embodiments, the akyl and the aryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

[0060] The term "azido," as used herein, represents a -N 3 group.

[0061] The term "cyano," as used herein, represents a CN group.

[0062] The terms "carbocyclyl," as used herein, refer to a non-aromatic C 3 -C 12 monocyclic, bicyclic, or tricyclic structure in which the rings are formed by carbon atoms. Carbocyclyl structures include cycloalkyl groups and unsaturated carbocyclyl radicals.

[0063] The term "cycloalkyl," as used herein, refers to a saturated, non-aromatic, monovalent mono- or polycarbocyclic radical of three to ten, preferably three to six carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.

[0064] The term "halo," as used herein, means a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) radical.

[0065] The term "heteroalkyl," as used herein, refers to an alkyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups. Examples of heteroalkyl groups are an "alkoxy" which, as used herein, refers alkyl-O- (e.g., methoxy and ethoxy). A heteroalkylene is a divalent heteroalkyl group.

[0066] The term "heteroalkenyl," as used herein, refers to an alkenyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkenyl groups. Examples of heteroalkenyl groups are an "alkenoxy" which, as used herein, refers alkenyl-O-. A heteroalkenylene is a divalent heteroalkenyl group.

[0067] The term "heteroalkynyl," as used herein, refers to an alkynyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkynyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkynyl groups. Examples of heteroalkynyl groups are an "alkynoxy" which, as used herein, refers alkynyl-O-. A heteroalkynylene is a divalent heteroalkynyl group.

[0068] The term "heteroaryl," as used herein, refers to an aromatic mono- or polycyclic radical of 5 to 12 atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, and S, with the remaining ring atoms being C. One or two ring carbon atoms of the heteroaryl group may be replaced with a carbonyl group. Examples of heteroaryl groups are pyridyl, pyrazoyl, benzooxazolyl, benzoimidazolyl, benzothiazolyl, imidazolyl, oxaxolyl, and thiazolyl.

[0069] The term "heteroarylalkyl," as used herein, represents an alkyl group substituted with a heteroaryl group. Exemplary unsubstituted heteroarylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C 1 -C 6 alkyl C 2 -C 9 heteroaryl, C 1 -C 10 alkyl C 2 -C 9 heteroaryl, or C 1 -C 20 alkyl C 2 -C 9 heteroaryl). In some embodiments, the akyl and the heteroaryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

[0070] The term "heterocyclyl," as used herein, denotes a mono- or polycyclic radical having 3 to 12 atoms having at least one ring containing one, two, three, or four ring heteroatoms selected from N, O or S, wherein no ring is aromatic. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, furyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, and 1,3-dioxanyl.

[0071] The term "heterocyclylalkyl," as used herein, represents an alkyl group substituted with a heterocyclyl group. Exemplary unsubstituted heterocyclylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C 1 -C 6 alkyl C 2 -C 9 heterocyclyl, C 1 -C 10 alkyl C 2 -C 9 heterocyclyl, or C 1 -C 20 alkyl C 2 -C 9 heterocyclyl). In some embodiments, the akyl and the heterocyclyl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

[0072] The term "hydroxyl," as used herein, represents an -OH group.

[0073] The term "N-protecting group," as used herein, represents those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 3rd Edition (John Wiley & Sons, New York, 1999). N-protecting groups include acyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine, leucine, and phenylalanine; sulfonyl-containing groups such as benzenesulfonyl, and p-toluenesulfonyl; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, and phenylthiocarbonyl, arylalkyl groups such as benzyl, triphenylmethyl, and benzyloxymethyl, and silyl groups, such as trimethylsilyl. Preferred N-protecting groups are alloc, formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

[0074] The term "nitro," as used herein, represents an NO 2 group.

[0075] The term "thiol," as used herein, represents an -SH group.

[0076] The alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl (e.g., cycloalkyl), aryl, heteroaryl, and heterocyclyl groups may be substituted or unsubstituted. When substituted, there will generally be 1 to 4 substituents present, unless otherwise specified. Substituents include, for example: aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl (e.g., substituted and unsubstituted cycloalkyl), halo (e.g., fluoro), hydroxyl, heteroalkyl (e.g., substituted and unsubstituted methoxy, ethoxy, or thioalkoxy), heteroaryl, heterocyclyl, amino (e.g., NH 2 or mono- or dialkyl amino), azido, cyano, nitro, or thiol. Aryl, carbocyclyl (e.g., cycloalkyl), heteroaryl, and heterocyclyl groups may also be substituted with alkyl (unsubstituted and substituted such as arylalkyl (e.g., substituted and unsubstituted benzyl)).

[0077] Compounds of the invention can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbents or eluant). That is, certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. "Enantiomer" means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms and represent the configuration of substituents around one or more chiral carbon atoms. Enantiomers of a compound can be prepared, for example, by separating an enantiomer from a racemate using one or more well-known techniques and methods, such as, for example, chiral chromatography and separation methods based thereon. The appropriate technique and / or method for separating an enantiomer of a compound described herein from a racemic mixture can be readily determined by those of skill in the art. "Racemate" or "racemic mixture" means a compound containing two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light. "Geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon- carbon double bond may be in an E (substituents are on opposite sides of the carbon- carbon double bond) or Z (substituents are oriented on the same side) configuration. "R," "S," "S*," "R*," "E," "Z," "cis," and "trans," indicate configurations relative to the core molecule. Certain of the disclosed compounds may exist in atropisomeric forms. Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9%) by weight relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure. Percent optical purity is the ratio of the weight of the enantiomer or over the weight of the enantiomer plus the weight of its optical isomer. Diastereomeric purity by weight is the ratio of the weight of one diastereomer or over the weight of all the diastereomers. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure. Percent purity by mole fraction is the ratio of the moles of the enantiomer or over the moles of the enantiomer plus the moles of its optical isomer. Similarly, percent purity by moles fraction is the ratio of the moles of the diastereomer or over the moles of the diastereomer plus the moles of its isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be understood that the name or structure encompasses either enantiomer of the compound free from the corresponding optical isomer, a racemic mixture of the compound or mixtures enriched in one enantiomer relative to its corresponding optical isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry and has two or more chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a number of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s) or mixtures of diastereomers in which one or more diastereomer is enriched relative to the other diastereomers. The invention embraces all of these forms.Definitions

[0078] In this application, unless otherwise clear from context, (i) the term "a" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and / or"; (iii) the terms "comprising" and "including" may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps; and (iv) the terms "about" and "approximately" may be understood to permit standard variation as would be understood by those of ordinary skill in the art; and (v) where ranges are provided, endpoints are included.

[0079] As used herein, the term "administration" refers to the administration of a composition (e.g., a compound, a complex or a preparation that includes a compound or complex as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) may be by any appropriate route. For example, in some embodiments, administration may be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal and vitreal.

[0080] As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to humans, at any stage of development. In some embodiments, "animal" refers to non-human animals, at any stage of development. In some embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and / or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and / or worms. In some embodiments, an animal may be a transgenic animal, genetically-engineered animal, and / or a clone.

[0081] As used herein, the terms "approximately" and "about" are each intended to encompass normal statistical variation as would be understood by those of ordinary skill in the art as appropriate to the relevant context. In certain embodiments, the terms "approximately" or "about" each refer to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of a stated value, unless otherwise stated or otherwise evident from the context (e.g., where such number would exceed 100% of a possible value).

[0082] Two events or entities are "associated" with one another, as that term is used herein, if the presence, level and / or form of one is correlated with that of the other. For example, a particular entity (e.g., polypeptide) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and / or form correlates with incidence of and / or susceptibility of the disease, disorder, or condition (e.g., across a relevant population).

[0083] In the practice of the uses of the present invention, an "effective amount" of any one of the compounds of the invention or a combination of any of the compounds of the invention or a pharmaceutically acceptable salt thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination.

[0084] As used herein, the term "combination therapy" refers to those situations in which a subject is simultaneously exposed to two or more therapeutic agents. In some embodiments, two or more compounds may be administered simultaneously; in some embodiments, such compounds may be administered sequentially; in some embodiments, such compounds are administered in overlapping dosing regimens.

[0085] As used herein, the term "dosage form" refers to a physically discrete unit of an active compound (e.g., a therapeutic or diagnostic agent) for administration to a subject. Each unit contains a predetermined quantity of active agent. In some embodiments, such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen). Those of ordinary skill in the art appreciate that the total amount of a therapeutic composition or compound administered to a particular subject is determined by one or more attending physicians and may involve administration of multiple dosage forms.

[0086] As used herein, the term "dosing regimen" refers to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic compound has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).

[0087] The term "pharmaceutical composition," as used herein, represents a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other pharmaceutically acceptable formulation.

[0088] A "pharmaceutically acceptable excipient," as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, and waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

[0089] As used herein, the term "pharmaceutically acceptable salt" means any pharmaceutically acceptable salt of the compound of formula (I). For example pharmaceutically acceptable salts of any of the compounds described herein include those that are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting a free base group with a suitable organic acid.

[0090] The compounds of the invention may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases and methods for preparation of the appropriate salts are well-known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases.

[0091] The term "pure" means substantially pure or free of unwanted components (e.g., other compounds and / or other components of a cell lysate), material defilement, admixture or imperfection.

[0092] Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and valerate salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.

[0093] As used herein, the term "stearoyl-CoA desaturase (SCD)-associated disorder" refers to an undesired physiological condition, disorder, or disease that is associated with and / or mediated at least in part by an SCD protein. In some instances, SCD-associated disorders are associated with excess SCD levels and / or activity. SCDs introduce a double bond in the C9-C10 position of saturated fatty acids such as palmitoyl-CoA and stearoyl-CoA which are converted to palmitoleoyl-CoA and oleoyl-CoA, respectively. One SCD gene, SCD1, has been characterized in humans for which there are two isoforms, SCD1 and SCD5. An SCD-associated disorder may be associated with and / or mediated at least in part by SCD1 and / or SCD5. Exemplary SCD-associated disorders include SCD-associated disorders include, but are not limited to metabolic disorders (e.g., diabetes (e.g., Type I diabetes and Type II diabetes), hyperglycemia, metabolic syndrome, obesity, lipid disorders, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and hypertension), cancer, cardiovascular diseases, cerebrovascular diseases, kidney diseases, liver diseases, skin disorders (e.g., acne (e.g., acne vulgaris)), central nervous system (CNS) disorders, dementia, multiple sclerosis, schizophrenia, mild cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, and dementia associated with Down Syndrome. Additional SCD-associated disorders are described herein or known in the art.

[0094] As used herein, the term "subject" refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). A subject may seek or be in need of treatment, require treatment, be receiving treatment, be receiving treatment in the future, or be a human or animal who is under care by a trained professional for a particular disease or condition.

[0095] As used herein, the terms "treat," "treated," or "treating" mean both therapeutic treatment and prophylactic or preventative measures wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder, or disease, or obtain beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of a condition, disorder, or disease; stabilized (i.e., not worsening) state of condition, disorder, or disease; delay in onset or slowing of condition, disorder, or disease progression; amelioration of the condition, disorder, or disease state or remission (whether partial or total), whether detectable or undetectable; an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder, or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.

[0096] A "therapeutic regimen" refers to a dosing regimen whose administration across a relevant population is correlated with a desired or beneficial therapeutic outcome.

[0097] The term "therapeutically effective amount" means an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and / or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and / or condition. In some embodiments, a therapeutically effective amount is one that reduces the incidence and / or severity of, and / or delays onset of, one or more symptoms of the disease, disorder, and / or condition. Those of ordinary skill in the art will appreciate that the term "therapeutically effective amount" does not in fact require successful treatment be achieved in a particular individual. Rather, a therapeutically effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment. It is specifically understood that particular subjects may, in fact, be "refractory" to a "therapeutically effective amount." To give but one example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable. In some embodiments, reference to a therapeutically effective amount may be a reference to an amount as measured in one or more specific tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweart, tears, urine, etc). Those of ordinary skill in the art will appreciate that, in some embodiments, a therapeutically effective amount may be formulated and / or administered in a single dose. In some embodiments, a therapeutically effective amount may be formulated and / or administered in a plurality of doses, for example, as part of a dosing regimen.Detailed Description

[0098] The disclosure features compounds useful for the treatment of neurological disorders, e.g., by inhibiting α-synuclein toxicity in a cell such as a neural cell, or by inhibiting SCD5 and / or SCD1 in a cell such as a neural cell. Exemplary compounds described herein include compounds having a structure according to Formula I: or pharmaceutically acceptable salts thereof.

[0099] In some embodiments, the compound has the structure of any one of compounds in Table 1. In some embodiments, the compound has the structure of any one of compounds in Table 2.

[0100] Other embodiments, as well as exemplary methods for the synthesis or production of these compounds, are described herein.Pharmaceutical Uses

[0101] The compounds described herein are useful in the methods of the invention and, while not bound by theory, are believed to exert their desirable effects through their ability to inhibit toxicity caused by protein aggregation, e.g., α-synuclein aggregation, in a cell.

[0102] Another aspect of the present invention relates to compounds for use in methods of treating and / or preventing neurological disorders such as neurodegenerative diseases in a subject in need thereof. The pathology of neurodegenerative disease may be characterized by the presence of inclusion bodies in brain tissue of affected patients.

[0103] In certain embodiments, neurological disorders that may be treated and / or prevented by the inventive compounds for use in the methods include, but are not limited to, Alexander disease, Alper' s disease, AD, amyotrophic lateral sclerosis, ataxia telangiectasia, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, multiple sclerosis, PD, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, Ref sum's disease, Sandhoff disease, Schilder' s disease, Steele-RichardsonOlszewski disease, tabes dorsalis, and Guillain-Barre Syndrome.

[0104] The compounds described herein are useful as inhibitors of stearoyl-CoA desaturase (SCD), including SCD1 and / or SCD5. SCD inhibitors are known in the art to be useful in methods of treating and / or preventing SCD-associated disorders. SCD-associated disorders are described, for example, in U.S. Patent No. 8,148,378, and in International Patent Application Publication Nos. WO 2011 / 047481, WO 2010 / 112520, WO 2010 / 045374, WO 2010 / 028761; WO 2009150196, and WO 2009 / 106991. Accordingly, another aspect of the present invention relates to compounds for use in methods of treating and / or preventing an SCD-associated disorder in a subject in need thereof.

[0105] SCD-associated disorders include metabolic disorders (e.g., insulin resistance, diabetes mellitus (e.g., Type I diabetes, Type II diabetes, non-insulin-dependent diabetes mellitus, gestational diabetes, and diabetic complications (e.g., diabetic peripheral neuropathy, diabetic nephropathy diseases, diabetic retinopathy, diabetic macroangiopathy, vascular complications of diabetes, and diabetic arteriosclerosis)), hyperglycemia, metabolic syndrome, hyperinsulinanemia, glucose intolerance, impaired glucose tolerance, body weight disorders (e.g., obesity (e.g., abdominal obesity), overweight, cachexia, body mass index, and anorexia), lipid disorders (e.g., abnormal lipid levels (e.g., elevated lipid levels, for example, in plasma), dyslipidemia (e.g., diabetic dyslipidemia), mixed dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypoalphalipoproteinemia, hyperbetalipoproteinemia, atherosclerosis, hypercholesterolemia (e.g., familial hypercholesterolemia), low HDL, high LDL, diseases related to accumulation of lipids in liver, familial histiocytic reticulosis, lipoprotein lipase deficiency, polyunsaturated fatty acid (PUFA) disorder, fatty acid desaturation index (e.g. the ratio of 18:1 / 18:0 fatty acids, or other fatty acids), and abnormal lipid metabolism disorders), disorders of abnormal plasma lipoprotein, disorders of pancreatic beta cell regeneration, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), hypertension, and microalbuminemia, leptin related diseases, hyperleptinaemia, appetite disorder, essential fatty acid deficiency, and adverse weight gain associated with a drug therapy).

[0106] Additional SCD-associated disorders include cancer, including solid tumors or hematological malignancies (e.g., esophageal cancer, pancreatic cancer, endometrial cancer, kidney cancer, hepatoma, thyroid cancer, gallbladder cancer, prostate cancer, leukemia (e.g., lymphomas and myelomas), ENT-related cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, uterine cancer, breast cancer, skin cancer, and prostate cancer), neoplasia, malignancy, metastases, tumors (benign or malignant), carcinogenesis, and hepatomas.

[0107] Further SCD-associated disorders include cardiovascular disease (e.g., heart disease, atherosclerosis, hypertension, lipidemia, dyslipidemia, elevated blood pressure, microalbuminemia, hyperuricaemia, hypercholesterolemia, hyperlipidemias, hypertriglyceridemias, arteriosclerosis, coronary artery disease, myocardial infarction, vascular complications of diabetes, and diabetic arteriosclerosis), inflammation, sinusitis, asthma, pancreatitis, osteoarthritis, rheumatoid arthritis, hepatitis (e.g., sexual hepatitis), meibomitis, cystic fibrosis, pre-menstrual syndrome, osteoporosis, thrombosis, cardiovascular risks, weight loss, angina, high blood pressure, ischemia, cardiac ischemia, reperfusion injury, angioplastic restenosis, infertility, liver disease (e.g., fatty liver, cirrhosis, nonalcoholic steatohepatitis, liver fibrosis, and hepatitis C related steatosis), kidney disease (e.g., tubulointerstitial fibrosis, kidney lipid accumulation, glomerular sclerosis, and proteinuria), osteoarthritis (e.g., osteoarthritis of the knee), gastro-esophageal disease, sleep apnea, secondary hyperparathyroidism of renal osteodystrophy, peripheral vascular disease, cerebrovascular disease (e.g., stroke, ischemic stroke and transient ischemic attack (TIA), and ischemic retinopathy), hyperandrogenism, malignant syndrome, extrapyramidal symptoms, hyperuricemia, hypercoagulability, syndrome X, cataract, polycystic ovary syndrome, breathing abnormalities, sleep-disordered breathing, low back pain, gout, gallstone disease, myopathies, lipid myopathies (e.g., carnitine palmitoyltransferase deficiency (CPT I or CPT II)), autoimmune diseases (e.g., lupus, host versus graft rejection, and rejection of organ transplants), asthma, inflammatory bowel diseases, nephropathy, retinopathy, erythrohepatic protoporphyria, iron overload disorders, and hereditary hemochromatosis.

[0108] Still further SCD-associated disorders include central nervous system (CNS) disorders, dementia, schizophrenia, mild cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, dementia associated with Down Syndrome, other neurodegenerative diseases, psychiatric disorders, eye diseases, immune disorders, multiple sclerosis, neuropathy, and depression.

[0109] Additional SCD-associated disorders include skin disorders (e.g., acne (e.g., acne vulgaris), psoriasis, hirsutism, rosacea, seborrheic skin, oily skin (syn seborrhea), seborrheic dermatitis, hyperseborrhea, eczema, keloid scar, skin ageing, diseases related to production or secretions from mucous membranes, wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, insufficient sebum secretion, oily hair, shiny skin, greasy-looking skin, greasy-looking hair, and other skin conditions caused by lipid imbalance).

[0110] An SCD-associated disorder can also include a disease or condition which is, or is related to, viral diseases or infections.

[0111] In some embodiments, the SCD-associated disorder is acne (e.g., acne vulgaris). In some embodiments, the SCD-associated disorder is diabetes (e.g., type II diabetes, including diabetes with inadequate glycemic control). In some embodiments, the SCD-associated disorder is nonalcoholic fatty liver disease (NAFLD). In some embodiments, the SCD-associated disorder is nonalcoholic steatohepatitis (NASH). In some embodiments, the SCD- associated disorder is cancer. In some embodiments, the SCD- associated disorder is obesity. In some embodiments, the SCD-associated disorder is metabolic syndrome (e.g., dyslipidemia, obesity, insulin resistance, hypertension, microalbuminemia, hyperuricaemia, and hypercoagulability), syndrome X, diabetes, insulin resistance, decreased glucose tolerance, non-insulin-dependent diabetes mellitus, Type II diabetes, Type I diabetes, diabetic complications, body weight disorders (e.g., obesity, overweight, cachexia, and anorexia), weight loss, body mass index, leptin related diseases, or a skin disorder (e.g., eczema, acne, psoriasis, and keloid scar). In some embodiments, the SCD-associated disorder is diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer's disease.Combination Formulations and Uses Thereof

[0112] The compounds of the invention can be combined with one or more therapeutic agents. In particular, the therapeutic agent can be one that treats or prophylactically treats any neurological disorder described herein.Combination Therapies

[0113] A compound of the invention can be used alone or in combination with other agents that treat neurological disorders or symptoms associated therewith, or in combination with other types of treatment to treat, prevent, and / or reduce the risk of any neurological disorders. In combination treatments, the dosages of one or more of the therapeutic compounds may be reduced from standard dosages when administered alone. For example, doses may be determined empirically from drug combinations and permutations or may be deduced by isobolographic analysis (e.g., Black et al., Neurology 65:S3-S6, 2005). In this case, dosages of the compounds when combined should provide a therapeutic effect.Pharmaceutical Compositions

[0114] The compounds of the invention are preferably formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo. Accordingly, in another aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention in admixture with a suitable diluent, carrier, or excipient.

[0115] The compounds of the invention may be used in the form of the free base, in the form of salts, solvates, and as prodrugs. All forms are within the scope of the invention. In accordance with the uses of the invention, the described compounds or salts, solvates, or prodrugs thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compounds of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.

[0116] A compound of the invention may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, a compound of the invention may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers.

[0117] A compound of the invention may also be administered parenterally. Solutions of a compound of the invention can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003, 20th ed.) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19), published in 1999.

[0118] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered via syringe.

[0119] Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels, and powders. Aerosol formulations typically include a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a propellant, which can be a compressed gas, such as compressed air or an organic propellant, such as fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer. Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, gelatin, and glycerine. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base, such as cocoa butter.

[0120] The compounds of the invention may be administered to an animal, e.g., a human, alone or in combination with pharmaceutically acceptable carriers, as noted herein, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice.Dosages

[0121] The dosage of the compounds of the invention, and / or compositions comprising a compound of the invention, can vary depending on many factors, such as the pharmacodynamic properties of the compound; the mode of administration; the age, health, and weight of the recipient; the nature and extent of the symptoms; the frequency of the treatment, and the type of concurrent treatment, if any; and the clearance rate of the compound in the animal to be treated. One of skill in the art can determine the appropriate dosage based on the above factors. The compounds of the invention may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response. In general, satisfactory results may be obtained when the compounds of the invention are administered to a human at a daily dosage of, for example, between 0.05 mg and 3000 mg (measured as the solid form). Dose ranges include, for example, between 10-1000 mg (e.g., 50-800 mg). In some embodiments, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of the compound is administered. Preferred dose ranges include, for example, between 0.05-15 mg / kg or between 0.5-15 mg / kg.

[0122] Alternatively, the dosage amount can be calculated using the body weight of the patient. For example, the dose of a compound, or pharmaceutical composition thereof, administered to a patient may range from 0.1-50 mg / kg (e.g., 0.25-25 mg / kg). In exemplary, non-limiting embodiments, the dose may range from 0.5-5.0 mg / kg (e.g., 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg / kg) or from 5.0-20 mg / kg (e.g., 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg / kg).EXAMPLES

[0123] The synthesis of compounds of this invention can be synthesized according to one or more of the general schemes of 1-13 shown below. The variables recited in the general schemes below are as defined for Formulae I, II, III, and IV.

[0124] An appropriately substituted alpha-halo aldehyde I (X a< is a halo, such as Cl or Br) can be condensed with urea or thiourea II to give appropiate 5-membered heterocycle III, where Y is either an O or S. This amine can be coupled with acid IV under a variety of conditions to provide the desired amide V.

[0125] An appropriately substituted alcohol I can be reacted with a haloated heterocycle such as II under basic conditions (eg cesium carbonate) to give ether intermediate III. Coupling of amine 3 with acid IV affords the desired heterocyclic compound V.

[0126] Coupling of amine I with acid II under a variety of coupling conditions affords the desired adduct III.

[0127] Appropriately substituted aldehyde or ketone I can be alkylated with heterocycle II (where X° is H or halide, usually bromide) under basic conditions (e.g. n-butyllithium) to give alcohol intermediate III. Deprotection of III under a variety of acidic conditions (e.g. trifluoroacetic acid ) gives amine IV. Coupling of this amine IV to acid V under a variety of coupling conditions affords desired compound VI. Alternatively, deoxygenation of IV strong under acidic conditions gives intermediate VII which can be coupled with acid V under a variety of coupling conditions to give amide VIII.

[0128] Appropriately substituted halide I can be reacted under metal catalysis conditions with appropriately substituted boronic ester II or acid III to give amine intermediate IV. Coupling of amine IV with appropriately substituted acid V under a variety of coupling conditions gives amide VI.

[0129] Condensation of di-acid I with appropriately substituted hydrazine II gives substituted acid III. Coupling with appropriately substituted amine IV under a variety of coupling conditions (e.g. HATU) gives amide V.

[0130] Condensation of appropriately substituted acid I with aminothiourea II gives appropriately substituted thiadiazole isomer III. Reaction of amine III with appropriately substituted acid IV under a variety of coupling conditions (e.g. HATU) yields amide V.

[0131] Pyridine I is alkylated with alkyl halide under basic conditions (e.g. potassium carbonate) to give two regioisomers II and III. The alkylated amide III is hydrolyzed under various conditions to give acid IV. Subsequent coupling with appropriately substituted amine V under various coupling conditions (e.g. HATU) affords amide VI.

[0132] An appropriately substituted phenol II is alkylated under basic conditions with pyridine I to give ether III. Reduction of nitro group in presence of iron affords amine intermediate IV. Coupling of IV with appropriately substituted acid V under a variety of coupling conditions gives VI.

[0133] Appropriately substituted halide I can be reacted under metal catalysis conditions with appropriately substituted boronic ester II to give amine intermediate III. Protection of amine III with a carbamate group (e.g. Boc) under standard conditions affords amine intermediate IV. Displacement of mesylate V with amine IV affords product VI which can be deprotected under standard acidic conditions to give amine VII.

[0134] Ester I can be coupled with a variety of alkyl halides II (where X c< is a halide, usually Br) to give alkylated pyridazinone III. Hydrolysis of ester under basic conditions (usually lithium hydroxide) gives acid intermediate IV. Coupling of acid IV with an appropriately substituted amine V under various peptide coupling conditions affords amide VI.

[0135] Appropriately substituted halide I (where X c< is typically a bromine) is reacted with aldehyde II under basic conditions (e.g. n-butyllithium) to give alcohol III. Global deprotection of PMB and Boc groups affords amine IV which can reacted with appropriately substituted acid V under a variety of coupling conditions to give amide VI.

[0136] Appropriately substituted halide I (usually X is a bromide) is converted to zincate II. Coupling of dichloride III with zincate II under metal catalysis conditions affords chloride IV. Reaction of IV with appropriately substituted amide V under metal catalysis conditions gives amide VI. Example 25. Preparation of N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (25)

[0137] Step 1: Preparation of 3-(bromomethyl)-5-fluorobenzonitrile

[0138]

[0139] A mixture of 3-fluoro-5-methylbenzonitrile (2.0 g, 14.8 mmol), N-bromosuccinimide (2.85 g, 16.3 mmol), 2,2'-azobis(2-methylpropionitrile) (242 mg, 1.48 mmol) in acetonitrile (20 mL) was stirred at reflux for 3 h. The mixture was concentrated. The reside was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 10 / 1) to afford 3-(bromomethyl)-5-fluorobenzonitrile (1.55 g, 6.96 mmol, 47%) as a light-yellow oil. 1< H NMR (500 MHz, Chloroform-d) δ 7.51 (s, 1H), 7.40 (dt, J = 2.0, 9.0 Hz, 1H), 7.33 (dt, J = 1.5, 8.0 Hz, 1H), 4.45 (s, 2H).Step 2: Preparation of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile

[0140]

[0141] A mixture of 3-(bromomethyl)-5-fluorobenzonitrile (1.0 g, 4.68 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.03 g, 4.68 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (0.380 g, 0.468 mmol), cesium carbonate (3.04 g, 9.36 mmol) in 1,4-dioxane (40 mL) was stirred at 100 °C for 3 h. The mixture was concentrated, and the crude material was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) to afford 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.720 g, 3.14 mmol, 67%) as a brown oil. LCMS (ESI) m / z: 228.1 [M+H] +< .Step 3: Preparation of N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0142]

[0143] To a solution of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.350 g, 1.54 mmol), 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.170 g, 1.11 mmol) in pyridine (10 mL) at 0 °C was added phosphorus(V) oxychloride (0.4 mL) dropwise. The reaction mixture was stirred at room temperature for 2 h. The mixture was poured into crushed ice and extracted with ethyl acetate (100 mL x 2). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, 10% methanol in ethyl acetate) and the obtained solid was washed with methanol (4 mL). The gray solid (0.070 g) was dissolved in minimal N,N-dimethylformamide and purified by prep-HPLC ( Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to give N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3 carboxamide (0.019 g, 0.052 mmol, 3.4%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ. 10.55 (s, 1H), 8.67 (d, J = 2.5 Hz, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.98 (dd, J = 3.0, 9.5 Hz, 1H), 7.75-7.68 (m, 3H), 7.58 (d, J = 9.5 Hz, 1H), 6.43 (d, J = 9.5 Hz, 1H), 4.03 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 363.1 [M+H] +< .Example 35. Preparation of N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (35)

[0144] Step 1: Preparation of 5-(3,4-difluorobenzyl)pyridin-2-amine

[0145]

[0146] To a solution of 4-(bromomethyl)-1 ,2-difluorobenzene (2.0 g, 9.71 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (2.14 g, 9.71 mmol) and potassium carbonate (2.7 g, 19.42 mmol) in tetrahydrofuran (20 mL) and water (5 mL) was added tetrakis(triphenylphosphine)palladium(0) (1.12 g, 0.971 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure and the aqueous layer was adjusted to pH = 1 with ~1 N hydrochloric acid. The aqueous layer was extracted with ethyl acetate (50 mL) before aqueous sodium bicarbonate added to adjust the pH = 8~10. The aqueous layer was extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were collected, dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, dichloromethane / methanol = 20 / 1) to offer 5-(3,4-difluorobenzyl)pyridin-2-amine as a yellow oil (800 mg, 3.64 mmol, 37%); LCMS (ESI) m / z: 221.1 [M+H] +< .Step 2: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

[0147]

[0148] To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.150 g, 0.892 mmol) in water (3 mL) was added sodium hydroxide (71 mg, 1.785 mmol). The reaction mixture was heated to 60 °C and stirred for 1 h. The reaction solution was treated with 1 N hydrochloric acid to adjust the pH value to 3~5 before all volatiles were removed to yield 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid as a white solid (110 mg, crude); LCMS (ESI) m / z: 155.1 [M+H] +< .Step 3: Preparation of N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0149]

[0150] To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (100 mg, 0.649 mmol) and diisopropylethylamine (252 mg, 1.947 mmol) in tetrahydrofuran (4 mL) at 20°C was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (370 mg, 0.974 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(3,4-difluorobenzyl)pyridin-2-amine (143 mg, 0.649 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 4 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, dichloromethane / methanol = 20 / 1) to offer N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (130.3 mg, 0.36 mmol, 55%) as a white solid. 1< H NMR (400 MHz, trifluoroacetic acid-d) δ 8.75-8.84 (m, 3H), 8.30 (d, J = 7.2 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.65-7.67 (m, 1H), 7.47-7.52 (m, 2H), 4.64 (s, 2H), 4.54 (s, 3H); LCMS (ESI) m / z: 357.1 [M+H] +< .Example 36. Preparation of N-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (36)

[0151] Step 1: Preparation of 5-(4-chlorobenzyl)pyridin-2-amine

[0152]

[0153] To a solution of 1-(bromomethyl)-4-chlorobenzene (1.0 g, 4.90 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.08 g, 4.90 mmol), potassium carbonate (1.35 g, 9.80 mmol), in tetrahydrofuran (12 mL) and water (3 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.566 g, 0.49 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure and the aqueous phase was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) to offer 5-(4-chlorobenzyl)pyridin-2-amine (0.55 g, 2.52 mmol, 51%) as a yellow solid. LCMS (ESI) m / z: 219.1 [M+H] +< .Step 2: Preparation of N-(6-(3-chlorobenzyl)pyridazin-3-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide

[0154]

[0155] To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.649 mmol), diisopropylethylamine (0.168 g, 1.298 mmol) in tetrahydrofuran (5 mL) at 20 °C, was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (370 mg, 0.974 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(4-chlorobenzyl)pyridin-2-amine (0.142 g, 0.649 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 4 h. The volatiles were removed under the reduced pressure and the crude residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to offer N-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (94.2 mg, 0.27 mmol, 41%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.11 (s, 1H), 8.31 (s, 1H), 8.07-8.09 (d, J = 8.4 Hz, 1H), 7.93-7.95 (d, J = 9.6 Hz, 1H), 7.71-7.73 (d, J = 8.4 Hz, 1H), 7.28-7.37 (m, 4H), 7.06-7.08 (d, J = 9.6 Hz, 1H), 3.96 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m / z: 355.1 [M+H] +< .Example 37. Preparation of N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (37)

[0156] Step 1: Preparation of N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0157]

[0158] A mixture of 5-(3,5-difluorobenzyl)pyridin-2-amine (200 mg, 0.9 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (139 mg, 0.9 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (513 mg, 1.35 mmol) and N,N-diisopropylethylamine (349 mg, 2.7 mmol) in N,N-dimethylformamide (8 mL) was stirred at room temperature for 1 h. The mixture was poured into water. The formed precipitate was collected by filtration and the obtained solid was washed with methanol (20 mL) to give N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.134 g, 0.38 mmol, 42%) as a grey solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.12 (s, 1H), 8.34 (d, J = 2.0 Hz, 1H), 8.07 (d, J = 10.5 Hz, 1H), 7.93 (d, J = 12.5 Hz, 1H), 7.76 (dd, J = 10.5, 3.0 Hz, 1H), 7.08-7.02 (m, 4H), 3.97 (s, 2H), 3.77 (s, 3H); LCMS (ESI) m / z: 357.1 [M+H] +< .Example 39. Preparation of 1-methyl-6-oxo-N-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide (39)

[0159] Step 1: Preparation of 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine

[0160]

[0161] To a solution of 1-(bromomethyl)-4-(trifluoromethyl)benzene (1.6 g, 6.7 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.77 g, 8 mmol) and potassium carbonate (1.85 g, 13.4 mmol) in acetonitrile (32 mL) and water (8 mL) was added 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.147 g, 0.67 mmol) under argon. The reaction mixture was stirred at 80 °C for 2 h. The reaction solution was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, dichloromethane / methanol = 100 / 1) to give 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine (1.2 g, 4.8 mmol, 71 %) as a color oil. LCMS (ESI) m / z: 253.1 [M+H] +< .Step 2: Preparation of 1-methyl-6-oxo-N-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide

[0162]

[0163] A solution of 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine (0.194 g, 0.77 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.154 g, 0.64 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.365 g, 0.96 mmol) and ethyldiisopropylamine (0.248 g, 1.92 mmol) in N,N-dimethylformamide (3.5 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 0.01% aqueous trifluoroacetic acid) to give 1-methyl-6-oxo-N-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide (0.0912 g, 0.24 mmol, 37.2%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.15 (s, 1H), 8.35 (d, J = 2.5 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.76 (dd, J = 8.5, 2.0 Hz, 1H), 7.67 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.07 (d, J = 9.5 Hz, 1H), 4.07 (s, 2H), 3.76 (s, 3H); LCMS (ESI) m / z: 389.0 [M+H] +< .Example 40. Preparation of N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (40)

[0164] Step 1: Preparation of 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine

[0165]

[0166] To a solution of 1-(bromomethyl)-3-chloro-5-fluorobenzene (2.23 g, 10 mmol), 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (2.67 g, 12 mmol) and potassium carbonate (2.76 g, 20 mmol) in 1,4-dioxane (45 mL) and water (15 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.732 g, 1.0 mmol) under nitrogen. The reaction mixture was stirred at 100 °C for 2 h. The volatiles were concentrated and water (50 mL) was added. The aqueous layer was extracted with ethyl acetate (80 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether / ethyl acetate from 1:1 to 0:1) to give 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (1.9 g, 8.1 mmol, 81%) as a brown solid. LCMS (ESI) m / z: 237.1 [M+H] +< .Step 2: Preparation of N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0167]

[0168] To a solution of 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (0.285 g, 1.2 mmol) in toluene (5 mL) at room temperature was added trimethylaluminum (0.6 mL, 1.2 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.168 g, 1.0 mmol) in toluene (5 mL) was added. The resulting solution was heated to 100 °C and stirred for 2 h. The reaction mixture was quenched with methanol and aqueous 2 N hydrochloric acid. The volatiles were removed under pressure and water (20 mL) was added. The aqueous layer was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to give N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.151 g, 0.41 mmol, 41%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.13 (s, 1H), 8.35 (d, J =2.0 Hz, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.94 (d, J = 10.0 Hz, 1H), 7.77 (dd, J 1 = 2.0 Hz, J 2 = 8.4 Hz, 1H), 7.24-7.28 (m,2H), 7.15-7.18(m, 1H), 7.06 (d, J = 10.0 Hz, 1H), 3.98 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m / z: 373.1 [M+H] +< .Example 42. Preparation of N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (42)

[0169] Step 1: Preparation of 3-(bromomethyl)-5-fluorobenzonitrile

[0170]

[0171] The synthesis of 3-(bromomethyl)-5-fluorobenzonitrile followed similar procedures as for Example 25. Compound 3-(bromomethyl)-5-fluorobenzonitrile (17.0 g, 79.4 mmol, 107%) was obtained as a colorless oil. 1< H NMR (500 MHz, Chloroform-d) δ 7.51 (s, 1H), 7.38 (dt, J = 2.5, 11.0 Hz, 1H), 7.32 (dt, J = 1.5, 10.0 Hz, 1H), 4.45 (s, 2H).Step 2: Preparation of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile

[0172]

[0173] The synthesis of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile was followed with similar procedures as for Example 23. Compound 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.800 g, 3.50 mmol, 50%) was obtained as a light-yellow oil. LCMS (ESI) for m / z: 228.1 [M+H] +< .Step 3: Preparation of N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0174]

[0175] A mixture of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.203 g, 1.32 mmol), 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.300 g, 1.32 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.752 g, 1.98 mmol), N,N-diisopropylethylamine (0.511 g, 3.96 mmol) in N,N-dimethylformamide (10 mL) was stirred at room temperature for 2 h. The mixture was poured into water. The formed precipitate was collected by filtration and washed with methanol (25 mL) to afford N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.198 g, 0.545 mmol, 41%) as an off-white solid. 1< H NMR (500 MHz, Trifluoroacetic acid-d) δ. 8.91-8.88 (m, 2H), 8.78 (d, J = 9.5 Hz, 1H), 8.39 (d, J = 4.0 Hz, 1H), 7.99-7.94 (m, 3H), 7.86 (d, J = 8.5 Hz, 1H), 4.80 (s, 2H), 4.57 (s, 3H); LCMS (ESI) m / z: 364.0 [M+H] +< .Example 43. Preparation of N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (43)

[0176] Step 1: Preparation of 3-((6-aminopyridin-3-yl)methyl)benzonitrile

[0177]

[0178] To a solution of 3-(bromomethyl)benzonitrile (0.980 g, 5 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.21 g, 5.5 mmol), potassium carbonate (1.38 g, 10 mmol) in acetonitrile (24 mL) and water (6 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.408 g, 0.5 mmol). Reaction was stirred at 80 °C for 2 h. The reaction mixture was extracted with ethyl acetate (50 mL x 2), washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, (dichloromethane: methanol = 13 / 1) to give 3-((6-aminopyridin-3-yl)methyl)benzonitrile (0.900 g, 4.31 mmol, 86.1%) as a brown liquid. LCMS (ESI) m / z: 210.1 [M+H] +< .Step 2: Preparation of N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0179]

[0180] A solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.65 mmol), 3-((6-aminopyridin-3-yl)methyl)benzonitrile (0.163 g, 0.78 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.371 g, 0.975 mol) and N,N-diisopropylethylamine (0.252 g, 1.95 mmol) in N,N-dimethylformamide (3 mL) was stirred at room temperature for 17 h. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01 % aqueous trifluoroacetic acid) to give N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0738 g, 0.174 mmol, 26.7%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.10 (s, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 9.7 Hz, 1H), 7.78 - 7.73 (m, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.53 (t, J = 7.7 Hz, 1H), 7.08 (d, J = 9.7 Hz, 1H), 4.03 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m / z: 346.1 [M+H] +< .Example 44. Preparation of N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (44)

[0181] Step 1: Preparation of 5-(3-methoxybenzyl)pyridin-2-amine

[0182]

[0183] To a solution of 1-(bromomethyl)-3-methoxybenzene (1.00 g, 5.00 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.21 g, 5.50 mmol), potassium carbonate (1.38 g, 10.0 mmol) in acetonitrile (24 mL) and water (6 mL) at room temperature was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.408 g, 0.500 mmol). Reaction was stirred at 80 °C for 2 h. The reaction mixture was extracted with ethyl acetate (50 mL x 2), washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, (dichloromethane / methanol = 13 / 1) to yield 5-(3-methoxybenzyl)pyridin-2-amine as a brown liquid (0.740 g, 3.46 mmol, 69.2%). LCMS (ESI) m / z: 215.1 [M+H] +< .Step 2: Preparation of N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0184]

[0185] A solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.65 mmol), 5-(3-methoxybenzyl)pyridin-2-amine (0.167 g, 0.78 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.371 g, 0.975 mmol) and N,N-diisopropylethylamine (0.252 g, 1.95 mmol) in N,N-dimethylformamide (3 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01 % aqueous trifluoroacetic acid) to give N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0787 g, 0.221 mmol, 34%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 8.31 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 9.7 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7.07 (d, J = 9.7 Hz, 1H), 6.84 - 6.77 (m, 3H), 3.93 (s, 2H), 3.78 (s, 3H), 3.72 (s, 3H); LCMS (ESI) for m / z: 351.1[M+H] +< .Example 45. Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (45)

[0186] Step 1: Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0187]

[0188] The synthesis of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3- carboxamide followed synthetic procedure reported for Example 43 . The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0206 g, 0.06 mmol, 14.3%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.21 (s, 1H), 8.34 (d, J = 2.0 Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 8.5 Hz 2.0 Hz, 1H), 7.38-7.33 (m, 1H), 7.14-7.02 (m, 3H), 3.99 (s, 2H), 3.79 (s, 3H); LCMS (ESI) m / z: 339.1 [M+H] +< .Example 46. Preparation of N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (46)

[0189] Step 1: Preparation of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine

[0190]

[0191] To a solution of 4-(bromomethyl)-1-chloro-2-fluorobenzene (0.500 g, 2.25 mmol), 6-aminopyridin-3-ylboronic acid (0.311 g, 2.25 mmol), potassium carbonate (0.621 g, 4.51 mmol) in tetrahydrofuran (8 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.260 g, 0.225 mmol) under nitrogen. The mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine as a yellow oil (0.300 g, crude); LCMS (ESI) m / z: 237.1 [M+H] +< . Used in the next step without additional purification.Step 2: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

[0192]

[0193] To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.200 g, 1.19 mmol) in water (1.5 mL) was added sodium hydroxide (0.095 g, 2.38 mmol). The reaction was heated to 60 °C and stirred for 1 h. The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and all volatiles were removed to afford 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.130 g, crude) as a white solid. LCMS (ESI) m / z: 155.1 [M+H] +< . Used in the next step without further purification.Step 3: Preparation of N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0194]

[0195] To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.130 g, 0.844 mmol), N,N-diisopropylethylamine (0.327 g, 2.53 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.481 g, 1.23 mmol). The reaction was stirred for 20 minutes before a solution of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.199 g, 0.844 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction mixture was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated. Purification by prep-HPLC gives N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.0262 g, 0.070 mmol, 8.3%). 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.14 (s, 1H), 8.34 (d, J = 1.6 Hz, 1H), 8.08 (d, J = 6.8 Hz, 1H), 7.95(d, J = 7.6 Hz, 1H), 7.75-7.77 (m, 1H), 7.52-7.54 (m, 1H), 7.33-7.35 (m, 2H), 7.08 (d, J = 8.0 Hz, 1H), 3.97 (s, 2H), 3.79 (s, 3H); LCMS (ESI) m / z: 373.0 [M+H] +< .Example 47. Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (47)

[0196] Step 1: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

[0197]

[0198] To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.100 g, 0.60 mmol) in water (1.2 mL) was added sodium hydroxide (0.048 g, 1.20 mmol). The mixture was stirred at 60 °C for 1 h. After being cooled to room temperature, hydrogen chloride (1N, 1.2 mL) was added and the aqueous phase was extracted with ethyl acetate (20 mL x 5). The combined organic layers were washed with brine (20 mL), dried with sodium sulfate, filtered and concentrated to afford 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.045 g, 0.29 mmol, 48.7%) as a white solid. LCMS (ESI) m / z: 155.1 [M+H] +< . Used in the next step directly without additional purification.Step 2: Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0199]

[0200] To a stirred solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.076 g, 0.35 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.045 g, 0.29 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.133 g, 0.35 mmol) in N,N-dimethylformamide (2.00 mL) was added N,N-diisopropylethylamine (0.112 g, 0.87 mmol). After addition, the reaction mixture was stirred at room temperature for 2 h. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.010 g, 0.028 mmol, 9.74%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.15 (s, 1H), 8.34 (d, J = 1.7 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 9.7 Hz, 1H), 7.76 (dd, J = 8.5, 2.1 Hz, 1H), 7.44 - 7.31 (m, 2H), 7.26 (dd, J = 16.1, 7.9 Hz, 2H), 7.08 (d, J = 9.7 Hz, 1H), 3.98 (s, 2H), 3.79 (s, 3H); LCMS (ESI) m / z: 355.0 [M+H] +< .Example 48. Preparation of of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (48)

[0201] Step 1: Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0202]

[0203] To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.153 g, 1 mmol) in dichloromethane (30 mL) at 0 °C was added N,N-dimethylformamide (2 drops) and oxalyl chloride (0.635 g, 5 mmol) dropwise. Reaction was warmed to room temperature over 2 h before it was concentrated. The crude solid was dissolved in dichloromethane (5 mL) and added to a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.262 g, 1.2 mmol) in pyridine (6 mL) at 0 °C Reaction mixture was warmed to room temperature over 2 h. Reaction was poured into ice water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (60 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide as a white solid (0.046 g, 0.13 mmol, 13%). 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.59 (s, 1H), 8.67 (d, J = 2.6 Hz, 1H), 8.31 (d, J = 2.1 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.98 (dd, J = 4.8 Hz, 4.8 Hz, 1H), 7.72 (dd, J = 8.6, 2.3 Hz, 1H), 7.35 (t, J = 6.0 Hz, 2H), 7.28-7.23 (m, 2H), 6.43 (d, J = 9.5 Hz, 1H), 3.97 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 354.1 [M+H] +< .Example 50. Preparation of N-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (50)

[0204] Step 1: Preparation of 1-(bromomethyl)-3-chloro-5-methoxybenzene

[0205]

[0206] To a solution of (3-chloro-5-methoxyphenyl)methanol (2.0 g, 11.6 mmol) in diethyl ether (20 mL) at 0 °C was added phosphorus tribromide (0.5 mL). The mixture was stirred for 2 h at 0 °C. Reaction mixture was poured into saturated aqueous sodium bicarbonate solution (150 mL) and extracted with ethyl acetate (200 mL x 2). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford 1-(bromomethyl)-3-chloro-5-methoxybenzene (2.15 g, 9.16 mmol, 79%) as a light-yellow solid. Used in the next step directly without additional purification.Step 2: Preparation of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine

[0207]

[0208] The synthesis of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine was following a similar procedure as for Example 23 to yield 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine (1.1 g, 4.40 mmol, 79%) as an orange solid. LCMS (ESI) m / z: 249.1 [M+H] +< .Step 3: Preparation of N-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0209]

[0210] A solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.200 g, 1.3 mmol) in thionyl chloride (15 mL) was stirred at 80 °C for 1 h. Once the suspension went clear volatiles were removed under reduced pressure. The crude residue was dissolved in dichloromethane (5 mL) and added slowly to a solution of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine (0.248 g, 1.0 mmol) and pyridine (0.240 g, 3.0 mmol) in dichloromethane (5 mL) at 0 °C. The resulting mixture was stirred at room temperature for another 2 h. The mixture was poured into water and extracted with dichloromethane (50 mL x 2). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, 10% methanol in ethyl acetate) to afford 250 mg of brown oil, The crude sample was dissolved in minimal N,N-dimethylformamide and purified by prep-HPLC ( Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to give N-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.148 g, 0.386 mmol, 38.6%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ. 10.59 (s, 1H), 8.67 (d, J = 2.5 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.98 (dd, J = 3.0, 9.5 Hz, 1H), 7.73 (dd, J = 2.5, 8.5 Hz, 1H), 6.90-6.84 (m, 3H), 6.43 (d, J = 9.5 Hz, 1H), 3.92 (s, 2H), 3.75 (s, 3H), 3.50 (s, 3H); LCMS (ESI) m / z: 384.1 [M+H] +< .Example 53. Preparation of N-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (53)

[0211] Step 1: Preparation of 5-(4-fluorobenzyl)pyridin-2-amine

[0212]

[0213] To a solution of 1-(bromomethyl)-4-fluorobenzene (3.0 g, 16.0 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (3.51 g, 16.0 mmol), potassium carbonate (4.4 g, 31.9 mmol) in tetrahydrofuran (48 mL) and water (12 mL) was added tetrakis(triphenylphosphine)palladium(0) (1.84 g, 1.60 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) affords 5-(4-fluorobenzyl)pyridin-2-amine (1.8 g, 8.96 mmol, 56%) as a yellow solid. LCMS (ESI) m / z: 203.1 [M+H] +< .Step 2: Preparation of N-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0214]

[0215] To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.200 g, 1.31 mmol), 5-(4-fluorobenzyl)pyridin-2-amine (0.264 g, 1.31 mmol) in pyridine (8 mL) at 20 °C was added phosphorus(V) oxychloride (0.595 g, 3.921 mmol). The reaction mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the crude solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide as a light-yellow solid (0.170 g, 0.503 mmol, 38.4%). 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.62 (s, 1H), 8.67 (s, 1H), 8.29 (s, 1H), 8.02 (d, J = 8 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.30 (t, J = 6 Hz, 2H), 7.12 (t, J = 8.3 Hz, 2H), 6.44 (t, J = 9.5 Hz, 2H), 3.95 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 338.1 [M+H] +< .Example 55. Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (55)

[0216] Step 1: Preparation of 5-(3-Fluorobenzyl)pyridin-2-amine

[0217]

[0218] To a solution of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (5.0 g, 22.72 mmol) in tetrahydrofuran (75 mL) and water (19 mL) at room temperature was added 1-(bromomethyl)-3-fluorobenzene (4.30 g, 22.7 mmol), tetrakis(triphenylphosphine)palladium(0) (2.63 g, 2.27 mmol) and potassium carbonate (6.27 g, 45.4 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 2 h, then cooled to room temperature and diluted with water (100 mL). Volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 2-3 with 4 N hydrogen chloride and extracted with ethyl acetate (80 mL x 2). The aqueous layer was then adjusted to pH = 9-10 with aqueous sodium carbonate and extracted with dichloromethane (80 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(3-fluorobenzyl)pyridin-2-amine (4.4 g, 21.8 mmol, 95.7 %) as a pale yellow solid. LCMS (ESI) m / z: 203.2 [M+H] +< .Step 2: Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0219]

[0220] A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (6.00 g, 39.2 mmol) in thionyl chloride (30 mL) was heated to 80 °C for 1 h. After being concentrated and dried in vacuo, the residue was dissolved in dry tetrahydrofuran (60 mL). This solution was added dropwise to a mixture of 5-(3-fluorobenzyl)pyridin-2-amine (6.00 g, 30.2 mmol) and pyridine (7.20 mL, 90.5 mmol) in dry tetrahydrofuran (60 mL) at 0 °C over 15 minutes. The reaction mixture was warmed to room temperature and stirred for 2 h. The white solid precipitate was collected by filtration and the filter cake was washed with ethanol (60 mL) and tert-butyl methyl ether (60 mL). The filtrate was concentrated, and the resulting solid was washed with ethanol (60 mL) and tert-butyl methyl ether (60 mL). Combined solids were dried in vacuo to give crude N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (7.3 g). The crude material (7.3 g) was dissolved in ethanol (1.10 L) at 80 °C. After being filtered, the filtrate was concentrated, to about 300 mL and cooled down to room temperature. The solid was collected by filtration and the filter cake was washed with ethanol (50 mL) and tert-butyl methyl ether (50 mL). The white solid was dried in vacuo to obtain N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (5.05 g, 15.0 mmol, 49.7%). 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 11.47 (s, 1H), 8.91 (d, J = 2.4 Hz, 1H), 8.36 (d, J = 1.8 Hz, 1H), 8.12 (d, J = 8.7 Hz, 1H), 8.06 - 7.94 (m, 2H), 7.42 - 7.28 (m, 1H), 7.14 (t, J = 8.6 Hz, 2H), 7.05 (dd, J = 9.0, 2.0 Hz, 1H), 6.47 (d, J = 9.6 Hz, 1H), 4.04 (s, 2H), 3.52 (s, 3H); LCMS (ESI) m / z: 338.0 [M+H] +< .Example 59. Preparation of N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (59)

[0221] Step 1: Preparation of 5-(3,5-difluorobenzyl)pyridin-2-amine

[0222]

[0223] To a solution of 1-(bromomethyl)-3,5-difluorobenzene (10.4 g, 50.2 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (12.2 g, 55.26 mmol) in 1,4-dioxane (240 mL) was added a solution of potassium carbonate (13.9 g, 100 mmol) in water (80 mL). The reaction mixture was degassed with nitrogen for 1 minute before 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (2.04 g, 2.50 mmol) was added and the mixture was degassed with nitrogen for 1 minute. The reaction mixture was stirred at 90 °C for 2 h and was concentrated and diluted with water (250 mL). The aqueous layer was extracted with ethyl acetate (300 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, ethyl acetate then dichloromethane: ethyl acetate=2:1) to afford compound 5-(3,5-difluorobenzyl)pyridin-2-amine (8.02 g, 36.4 mmol, 72%) as a pale yellow solid. The pale yellow solid (4.6 g) was re- purified by column chromatography (silica gel, dichloromethane: ammonia in methanol (7 N) = 20 / 1) to afford 5-(3,5-difluorobenzyl)pyridin-2-amine (4.4 g, 20 mmol, 95%) as a pale yellow solid. LCMS (ESI) m / z: 221.1 [M+H] +< .Step 2: Preparation of N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0224]

[0225] A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (4.0 g, 26 mmol) in thionyl chloride (40 mL) was heated to 80 °C for 1 h. After being concentrated and dried in vacuo, the residue was dissolved in dry tetrahydrofuran (100 mL) and added to a mixture of 5-(3,5-difluorobenzyl)pyridin-2-amine (4.4 g, 20 mmol) and pyridine (8.0 g, 100 mmol) in dry tetrahydrofuran (50 mL) at room temperature over 1 h. The reaction mixture was stirred at room temperature for 20 h. The yellow solid precipitated out of the reaction solution and was collected by filtration. The filter cake was washed with ethanol (50 mL) and tert-butyl methyl ether (50 mL). The filtrate was concentrated, and the residue was washed with ethanol (20 mL) and tert-butyl methyl ether (20 mL). Combined both solids and dried in vacuo to give crude N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (4.1 g) which was dissolved in ethanol (500 mL) at 110 °C. After being filtered, the filtrate was cooled to room temperature. The solid was collected by filtration and the cake was washed with ethanol (50 mL) and tert-butyl methyl ether (50 mL). The off-white solid was slurring in water for 3 h before filtered and dried over vacuo to give N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (2.9 g, 8.17 mmol, 41%) as an off-white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.55 (s, 1H), 8.66 (d, J =2.4 Hz, 1H), 8.31 (d, J = 1.6 Hz, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.97 (dd, J 1 = 2.4 Hz, J 2 = 9.6 Hz, 1H), 7.71 (dd, J 1 = 2.4 Hz, J 2 = 8.8 Hz, 1H), 7.02-7.08 (m, 3H), 6.42 (d, J = 9.6 Hz, 1H), 3.96 (s, 2H), 3.49 (s, 3H); LCMS (ESI) m / z: 356.0 [M+H] +< .Example 60. Preparation of N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (60)

[0226] Step 1: Preparation of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine

[0227]

[0228] To a solution of 4-(bromomethyl)-2-chloro-1-fluorobenzene (1.12 g, 5 mmol), 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (1.34 g, 6 mmol) and potassium carbonate (1.38 g, 10 mmol) in 1,4-dioxane (30 mL) and water (10 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.366 g, 0.5 mmol) under nitrogen. The reaction mixture was stirred at 100 °C for 2 h. The reaction mixture was concentrated, and water (50 mL) was added. The aqueous phase was extracted with ethyl acetate (80 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether / ethyl acetate from 1 / 1 - 0 / 1) to give 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (870 mg, 74%) as a yellow solid. LCMS (ESI) m / z: 237.1 [M+H] +< .Step 2: Preparation of N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0229]

[0230] To a solution of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.142 g, 0.6 mmol) and 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.092 g, 0.6 mmol) in pyridine (4 mL) at room temperature was added phosphorus oxychloride (0.276 g, 1.8 mmol) slowly under argon. The reaction mixture was stirred at room temperature for 1.5 h. The reaction mixture was concentrated, and water (30 mL) was added. The aqueous layer was extracted with dichloromethane (30 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (BostonC18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to give N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (14.3 mg, 0.04 mmol, 6.5%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.53 (s, 1H), 8.65 (d, J =2.8 Hz, 1H), 8.30 (d, J = 2.0 Hz, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.96 (dd, J 1 = 2.8 Hz, J 2 = 9.6 Hz, 1H), 7.68 (dd, J 1 = 2.4 Hz, J 2 = 8.4 Hz, 1H), 7.51 (dd, J 1 = 2.0 Hz, J 2 = 6.8 Hz, 1H), 7.32 - 7.36 (m, 1H), 7.25 - 7.29 (m, 1H), 6.42 (d, J = 9.2 Hz, 1H), 3.94 (s, 2H), 3.48 (s, 3H); LCMS (ESI) m / z: 372.0 [M+H] +< .Example 62. Preparation of N-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-car boxamide (62)

[0231] Step 1: Preparation of N-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxami de

[0232]

[0233] A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.081 g, 0.531 mmol) in thionyl chloride (3 mL) was stirred at 80 °C for 0.5 h under nitrogen. The reaction mixture was concentrated, dissolved in dichloromethane (3 mL) and added to a solution of 5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-amine (0.100 g, 0.442 mmol) in pyridine (3 mL) at 0 °C. The reaction mixture was then stirred at 0 °C ~ room temperature for 2 h. The reaction solution was poured into ice water and extracted with dichloromethane (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to give N-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxami de (0.0885 g, 0.245 mmol, 55.3%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.61 (s, 1H), 8.66 (d, J = 2.8 Hz, 1H), 8.29 (d, J = 1.6 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.97 (dd, J = 9.6, 2.8 Hz, 1H), 7.70 (dd, J = 8.8, 2.4 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 6.8 Hz, 2H), 6.43 (d, J = 9.6 Hz, 1H), 4.95 (s, 4H), 3.97 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 362.1 [M+H] +< .Example 63. Preparation of 1-methyl-6-oxo-N-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide (63)

[0234] Step 1: Preparation of 1-methyl-6-oxo-N-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide

[0235]

[0236] A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.184 g, 1.2 mmol) in thionyl chloride (4 mL) was stirred at 80 °C for 0.5 h under nitrogen. The reaction mixture was concentrated, dissolved in dichloromethane (6 mL) and added to a solution of 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine (0.252 g, 1 mmol) in pyridine (6 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h and was poured into ice water. The aqueous layer was extracted with dichloromethane (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 0.01% aqueous trifluoroacetic acid) to give 1-methyl-6-oxo-N-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide (0.1955 g, 0.51 mmol, 50.5%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.60 (s, 1H), 8.67 (d, J = 2.4 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.97 (dd, J = 9.6, 2.8 Hz, 1H), 7.72 (dd, J = 8.8, 2.8 Hz, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 6.43 (d, J = 9.6 Hz, 1H), 4.07 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 388.1 [M+H] +< .Example 64. Preparation of N-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (64)

[0237] Step 1: Preparation of N-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0238]

[0239] To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.653 mmol), 5-(4-chlorobenzyl)pyridin-2-amine (0.142 g, 0.653 mmol) in pyridine (4 mL) at 20 °C was added phosphorus oxychloride (0.297 g, 1.96 mmol). The reaction mixture was stirred at 20 °C for 2 h. The volatiles were removed under reduced pressure. The crude solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 0.01% aqueous trifluoroacetic acid) to offer N-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (29.6 mg, 0.084 mmol, 13%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.55 (s, 1H), 8.66-8.67 (d, J = 2.4 Hz, 1H), 8.28 (s, 1H), 7.96-8.05 (m, 2H), 7.66-7.69 (q, J = 3.6 Hz, 1H), 7.27-7.38 (m, 4H), 6.42-6.44 (d, J = 9.6 Hz, 1H), 3.95 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 354.1 [M+H] +< .Example 66. Preparation of N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (66)

[0240] Step 1: Preparation of N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0241]

[0242] To a solution of 1-methyl-6-oxo-1 ,6-dihydropyridine-3-carboxylic acid (100 mg, 0.653 mmol) and 5-(3,4-difluorobenzyl)pyridin-2-amine (144 mg, 0.653 mmol) in pyridine (4 mL) at 20 °C, was added phosphorus oxychloride (297 mg, 1.96 mmol). The reaction mixture was stirred at 20 °C for 4 h. The volatiles were removed under reduced pressure, and the resulting crude solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (39.8 mg, 0.11 mmol, 17%) as a light-yellow solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.56 (s, 1H), 8.67 (d, J = 2.0 Hz, 1H), 8.30 (s, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 2.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.33-7.40 (m, 2H), 7.10-7.13 (m, 1H), 6.43 (d, J = 9.6 Hz, 1H), 3.95 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 356.0 [M+H] +< .Example 67. Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (67)

[0243] Step 1: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

[0244]

[0245] To a solution of methyl 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.637 g, 3.5 mmol) in tetrahydrofuran (5 mL) and water (1.5 mL) was added sodium hydroxide (0.280 g, 7 mmol). The reaction mixture was stirred at room temperature for 3 h before it was neutralized to pH = 6 with aqueous 1 N hydrogen chloride. The mixture was concentrated, to 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid as a white solid (0.900 g, crude); LCMS (ESI) m / z: 169.1 [M+H] +< . Used in the next step without additional purification.Step 2: Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0246]

[0247] A solution of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.6 mmol), 5-(3-chlorobenzyl)pyridin-2-amine (0.157 g, 0.75 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.342 g, 0.9 mmol) and N,N-diisopropylethylamine (0.232 mg, 1.8 mmol) in tetrahydrofuran (4 mL) was stirred at room temperature for 2 h. Volatiles were removed under reduced pressure. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.050 g, 0.136 mmol, 22.6%). 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.23 (s, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 4.8 Hz, 1H), 7.78 (dd, J = 4.2, 4.0 Hz, 1H), 7.36-7.32 (m, 2H), 7.28-7.23 (m, 2H), 7.07 (d, J = 9.2 Hz, 1H), 4.24-4.18 (m, 2H), 3.99 (s, 2H), 1.35 (t, J = 7.2 Hz, 3H); LCMS (ESI) 369.1 [M+H] +< .Example 68. Preparation of 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (68)

[0248] Step 1: Preparation of 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0249]

[0250] A solution of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (120 mg, 0.71 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (162 mg, 0.86 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (405 mg, 1.065 mol) and N-N,N-diisopropylethylamine (275 mg, 2.13 mmol) in tetrahydrofuran (4 mL) was stirred at room temperature for 2 h. Volatiles were removed under reduced pressure. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.0973 g, 0.275 mmol, 38.8%). 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.21 (s, 1H), 8.34 (d, J = 2.0 Hz, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 10.0 Hz, 1H), 7.77 (dd, J = 4.2, 4.2 Hz, 1H), 7.37-7.32 (m, 1H), 7.13-7.01 (m, 4H), 4.23-4.18 (m, 2H), 3.99 (s, 2H), 1.34 (t, J = 7.2 Hz, 3H); LCMS (ESI) m / z: 353.1 [M+H] +< .Example 69. Preparation of N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (69)

[0251] Step 1: Preparation of 3-(bromomethyl)-5-fluorobenzonitrile

[0252]

[0253] The synthesis of 3-(bromomethyl)-5-fluorobenzonitrile was followed using similar procedure to Example 25. Product 3-(bromomethyl)-5-fluorobenzonitrile (17.0 g, 79.4 mmol, 107%) was obtained as a colorless oil. 1< H NMR (500 MHz, Chloroform-d) δ 7.51 (s, 1H), 7.38 (dt, J = 2.5, 11.0 Hz, 1H), 7.32 (dt, J = 1.5, 10.0 Hz, 1H), 4.45 (s, 2H).Step 2: Preparation of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile

[0254]

[0255] The synthesis of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile was following similar procedures to Example 23. Product 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (800 mg, 3.5 mmol, 50%) was obtained as a light-yellow oil. LCMS (ESI) m / z: 228.1 [M+H] +< .Step 3: Preparation of N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0256]

[0257] The synthesis of N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide followed similar procedures as for Example 42. Compound N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.180 g, 0.478 mmol, 43.4%) was obtained as an off-white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.19 (s, 1H), 8.38 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 9.0 Hz, 1H), 7.94 (d, J = 9.5 Hz, 1H), 7.80 (dd, J = 2.5, 9.0 Hz, 1H), 7.72-7.69 (m, 2H), 7.58 (d, J = 10.0 Hz, 1H), 7.07 (d, J = 9.5 Hz, 1H), 4.20 (q, J = 7.0 Hz, 2H), 4.05 (s, 2H), 1.35 (t, J = 7.0 Hz, 3H); LCMS (ESI) m / z: 378.1 [M+H] +< .Example 70. Preparation of N-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (70)

[0258] Step 1: Preparation of N-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0259]

[0260] A solution of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.127 g, 0.75 mmol), 5-(3,4-dichlorobenzyl)pyridin-2-amine (0.230 g, 0.90 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.427 g, 1.125 mmol) and N,N-diisopropylethylamine (0.290 g, 2.25 mmol) in tetrahydrofuran (4 mL) was stirred at room temperature for 16 h. Then the reaction mixture was concentrated, and the crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.0679 g, 0.141 18.8%). 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.20 (s, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.94 (d, J = 9.7 Hz, 1H), 7.76 (dd, J = 8.5, 2.3 Hz, 1H), 7.57 (t, J = 5.4 Hz, 2H), 7.27 (dd, J = 8.3, 2.0 Hz, 1H), 7.07 (d, J = 9.7 Hz, 1H), 4.21 (t, J = 7.2 Hz, 2H), 3.99 (s, 2H), 1.34 (t, J = 7.2 Hz, 3H); LCMS (ESI) m / z: 403.0 [M+H] +< .Example 71. Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide (71)

[0261] Step 1: Preparation of methyl 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylate

[0262]

[0263] To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (1.0 g, 6.49 mmol), potassium carbonate (2.68 g, 19.5 mmol) in N,N-dimethylformamide (15.0 mL) was added 1-iodopropane (1.65 g, 9.74 mmol). The reaction mixture was heated to 60 °C and stirred for 3 h. The reaction solution was dissolved in ethyl acetate (50 mL) and washed with water (50 mL), dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel, petroleumether / ethyl acetate = 1 / 1) to afford methyl 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylate (0.700 g, 3.57 mmol, 55%) as a white solid. LCMS (ESI) m / z: 197.2 [M+H] +< .Step 2: Preparation of 6-oxo-1-propyl-1 ,6-dihydropyridazine-3-carboxylic acid

[0264]

[0265] Sodium hydroxide (81.6 mg, 2.04 mmol) was added to a mixture of methyl 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylate (200 mg, 1.02 mmol), tetrahydrofuran (4 mL) and water (2 mL) before the reaction was heated to 60 °C and stirred for 1 h. 1 N hydrochloric acid was added to adjust the pH value to 3~5 before all the solvent was removed to offer crude 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylic acid (200 mg, crude).Step 3: Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide

[0266]

[0267] To a mixture of 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylic acid (0.120 g, 0.659 mmol), diisopropylethylamine (0.255 g, 1.977 mmol) and tetrahydrofuran (5 mL) at 20°C was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.376 g, 0.659 mmol). The reaction solution was stirred for 20 minutes before a solution of 6-(3-chlorobenzyl)pyridazin-3-amine (0.144 g, 0.659 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 16 h. The solvent was removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 0.01% aqueous trifluoroacetic acid) to offer N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide (178.0 mg, 0.49 mmol, 74%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.16 (s, 1H), 8.34 (s, 1H), 8.08-8.10 (d, J = 8.4 Hz, 1H), 7.92-7.95 (d, J = 9.6 Hz, 1H), 7.75-7.78 (m, 1H), 7.32-7.36 (m, 1H), 7.04-7.14 (m, 4H), 4.12-4.16 (t, J = 7.2 Hz, 2H), 3.99 (s, 2H), 1.78-1.84 (q, J = 7.4 Hz, 2H), 0.90-0.94 (t, J = 7.4 Hz, 3H); LCMS (ESI) m / z: 367.1 [M+H] +< .Example 72. Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (72)

[0268] Step 1: Preparation of methyl 1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate

[0269]

[0270] To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (1.0 g, 6.49 mmol) and potassium carbonate (2.68 g, 19.47 mmol) in N,N-dimethylformamide (15.0 mL) at room temperate was added 2-iodopropane (1.65 g, 9.74 mmol). The reaction mixture was heated to 60 °C and stirred for 1 h. The reaction mixture was dissolved in ethyl acetate (50 mL) and washed with water (50 mL), dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) to offer methyl 1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate as a white solid (0.500 g, 2.55 mmol, 39%) as a white solid. LCMS (ESI) m / z: 197.1 [M+H] +< .Step 2: Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0271]

[0272] To a solution of 5-(3-fluorobenzyl)pyridin-2-amine (0.206 g, 1.02 mmol) in toluene (10 mL) at 20 °C was added trimethylaluminum (0.5 mL, 1.02 mmol, 2 M in toluene) under argon. The reaction mixture was stirred at 20 °C for 1 h before a solution of methyl 1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.100 g, 0.51 mmol) in toluene (5 mL) was added. The reaction solution was stirred at 100 °C for 2 h. The solvent was removed under reduced pressure and the residue was treated with a mixture of 1 N hydrochloric acid (5 mL) and methanol (20 mL). The volatiles were removed under reduced pressure and the crude product was dissolved in dichloromethane (50 mL) and water (50 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 0.01% aqueous trifluoroacetic acid) to offer

[0273] N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0832 g, 0.23 mmol, 45%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.12 (s, 1H), 8.35 (s, 1H), 8.07-8.09 (d, J = 8.4 Hz, 1H), 7.91-7.94 (d, J = 9.6 Hz, 1H), 7.74-7.77 (m, 1H), 7.32-7.38 (m, 1H), 7.01-7.13 (m, 4H), 5.15-5.19 (t, J = 6.6 Hz, 1H), 3.99 (s, 2H), 1.38-1.40 (d, J = 6.4 Hz, 6H); LCMS (ESI) m / z: 367.1 [M+H] +< .Example 73. Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (73)

[0274] Step 1: Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0275]

[0276] To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.222 g, 1.02 mmol) in toluene (15 mL) at 20 °C was added trimethylaluminum (0.5 mL, 1.02 mmol, 2 M in toluene) under argon. The reaction mixture was stirred at 20 °C for 1 h before a solution of methyl 1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.100 g, 0.51 mmol) in toluene (15 mL) was added. The reaction solution was stirred at 100 °C for 2 h. The volatiles were removed under reduced pressure and the residue was quenched with water (50 mL) and extracted with dichloromethane (50 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 0.01% aqueous trifluoroacetic acid) to offer N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (107.8 mg, 0.28 mmol, 55%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.11 (s, 1H), 8.36 (s, 1H), 8.07-8.09 (d, J = 8.0 Hz, 1H), 7.92-7.94 (d, J = 9.6 Hz, 1H), 7.75-7.77 (d, J = 8.0 Hz, 1H), 7.23-7.35 (m, 4H), 7.05-7.07 (d, J = 9.6 Hz, 1H), 5.16-5.19 (t, J = 6.6 Hz, 1H), 3.99 (s, 2H), 1.39-1.40 (d, J = 6.8 Hz, 6H); LCMS (ESI) m / z: 383.1 [M+H] +< .Example 74. Preparation of N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxami de (74)

[0277] Step 1: Preparation of N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0278]

[0279] A solution of 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.126 g, 0.7 mmol), 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (0.198 g, 0.84 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.400 g, 1.05 mmol) and N,N-diisopropylethylamine (0.271 g, 2.1 mmol) in N,N-dimethylformamide (3.5 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.104 g, 0.262 mmol, 37.4%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.12 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.91 (d, J = 9.7 Hz, 1H), 7.78 (dd, J = 8.5, 2.3 Hz, 1H), 7.30 - 7.22 (m, 2H), 7.17 (d, J = 9.5 Hz, 1H), 7.06 (d, J = 9.7 Hz, 1H), 4.10 - 4.06 (m, 1H), 4.00 (s, 2H), 1.28 - 1.24 (m, 2H), 1.04 - 1.00 (m, 2H); LCMS (ESI) m / z: 399.1 [M+H] +< .Example 75. Preparation of 1-cyclopropyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (75)

[0280] Step 1: Preparation of methyl 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate

[0281]

[0282] Combined methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (0.400 g, 2.59 mmol) with cyclopropylboronic acid (0.444 g, 5.18 mmol) and copper(II) acetate (0.940 g, 5.18 mmol) and suspended in 1,2-dichloroethane (8.63 mL). Added triethylamine (1.43 mL, 10.3 mmol) and pyridine (1.04 mL, 12.9 mmol). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Stirred for 16 h at 80 °C. Cooled to room temperature and quenched with saturated aqueous ammonium chloride (15 mL). Extracted with dichloromethane (10 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate / hexanes through 40 g of silica gel) to give methyl 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate as a yellow solid (155 mg, 0.798 mmol, 31%). 1< H NMR (300 MHz, Chloroform-d) δ 7.99 (d, J = 9.7 Hz, 1H), 7.10 (d, J = 9.7 Hz, 1H), 4.43 - 4.26 (m, 1H), 4.11 (s, 3H), 1.49 - 1.19 (m, 4H).Step 2: Preparation of 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

[0283]

[0284] Dissolved methyl 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.135 g, 0.6951 mmol) in tetrahydrofuran (2.0 mL) and added lithium hydroxide hydrate (0.087 g, 2.08 mmol) and water (0.5 mL). Stirred at room temperature 16 h. Monitored reaction by LC / MS. Upon completion, quenched with 10% aqueous hydrochloric acid (7 mL) until acidic (pH ~3). Extracted with ethyl acetate (15 mL). Washed with brine (10 mL), then dried over sodium sulfate, filtered, and concentrated to give 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid, as a beige solid (80 mg, 0.444 mmol, 64%). 1< H NMR (300 MHz, Chloroform-d) δ 7.90 (d, J = 9.7 Hz, 1H), 7.03 (d, J = 9.7 Hz, 1H), 4.24 - 4.08 (m, 1H), 1.26 - 1.09 (m, 4H).Step 3: Preparation of 1-cyclopropyl-N-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0285]

[0286] Combined 5-[(3-fluorophenyl)methyl]pyridin-2-amine (0.076 g, 0.3758 mmol) with 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.068 g, 0.3758 mmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.121 g, 0.3758 mmol) in a 25mL round bottom flask. Suspended in dichloromethane (4 mL) and added ethylbis(propan-2-yl)amine (98.1 µL, 0.5637 mmol). Stirred 16 h at room temperature. Concentrated reaction to remove solvent. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate / hexanes through 24 g of silica gel) to give 1-cyclopropyl-N-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide (48 mg, 0.132 mmol, 35%) as a white solid. 1< H NMR (300 MHz, Chloroform-d) δ 9.27 (s, 1H), 8.30 - 8.20 (m, 2H), 8.03 (d, J = 9.7 Hz, 1H), 7.57 (dd, J = 8.6, 2.5 Hz, 1H), 7.30 (d, J = 2.0 Hz, 1H), 7.14 - 6.85 (m, 4H), 4.20 - 4.04 (m, 1H), 3.99 (s, 2H), 1.27 - 1.10 (m, 4H); LCMS (ESI) m / z: 365.5 [M+H] +< .Example 76. Preparation of N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxami de (76)

[0287] Step 1: Preparation of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine

[0288]

[0289] To a solution of 4-(bromomethyl)-2-chloro-1-fluorobenzene (1.12 g, 5 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.32 g, 6 mmol) and potassium carbonate (1.38 g, 10 mmol) in acetonitrile (24 mL) and water (6 mL) at room temperature was added 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.408 g, 0.5 mmol) under argon. The reaction mixture was stirred at 80 °C for 2 h. The reaction mixture was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 2 / 3) to give 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.8 g, 3.4 mmol, 67.8%) as a brown solid. LCMS (ESI) m / z: 237.1 [M+H] +< .Step 2: Preparation of N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0290]

[0291] A solution of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.198 g, 0.84 mmol), 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.126 g, 0.7 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (400 mg, 1.05 mmol) and ethyldiisopropylamine (271 mg, 2.1 mmol) in N,N-dimethylformamide (3.5 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (71.4 mg, 0.18 mmol, 25.7%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.11 (s, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.90 (d, J = 10.0 Hz, 1H), 7.74 (dd, J = 8.5, 2.5 Hz, 1H), 7.51 (dd, J = 7.5, 2.0 Hz, 1H), 7.35 (t, J = 8.8 Hz, 1H), 7.29 - 7.26 (m, 1H), 7.06 (d, J = 10.0 Hz, 1H), 4.10 - 4.07 (m, 1H), 3.97 (s, 2H), 1.28 - 1.23 (m, 2H), 1.04 - 1.00 (m, 2H); LCMS (ESI) m / z: 399.0 [M+H] +< .Example 77. Preparation of 1-(cyclopropylmethyl)-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamid e (77)

[0292] Step 1: Preparation of 5-[(3-fluorophenyl)methyl]pyridin-2-amine

[0293]

[0294] In a 40 mL reaction vial, combined 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.500 g, 2.27 mmol), tripotassium phosphate (0.721 g, 3.40 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.080 g, 0.1135 mmol). Added tetrahydrofuran (3.0 mL) and water (1.0 mL) and added 1-(bromomethyl)-3-fluorobenzene (278 µL, 2.27 mmol). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. The reaction was heated at 75 °C for 16 h. Cooled the reaction to room temperature and diluted with ethyl acetate (15 mL). Washed the organic layer with water (10 mL), then brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate / hexanes through 24 g of silica gel) to give 5-[(3-fluorophenyl)methyl]pyridin-2-amine (33 mg, 0.163 mmol, 7%) as a yellow oil. 1< H NMR (300 MHz, Chloroform-d) δ 8.31 - 8.17 (m, 2H), 8.04 (d, J = 9.7 Hz, 1H), 7.04 (d, J = 9.7 Hz, 1H), 7.02 - 6.87 (m, 2H), 3.99 (s, 2H).Step 2: Preparation of 1-(cyclopropylmethyl)-N-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-oxo-1,6-dihydropyridazine-3-carboxami de

[0295]

[0296] Dissolved 5-[(3-fluorophenyl)methyl]pyridin-2-amine (0.033 g, 0.1631 mmol) in methylene chloride (2.0 mL) and added 1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.032 g, 0.1631 mmol), [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl})oxidanium; tetrafluoroboranuide (0.053 mg, 0.1631 mmol) and ethylbis(propan-2-yl)amine (42.5 µL, 0.2446 mmol). Stirred at room temperature 16 h. Directly purified reaction by column chromatography (eluting with 0-100% ethyl acetate / hexanes through 12 g of silica gel) to give 1-(cyclopropylmethyl)-N-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-oxo-1,6-dihydropyridazine-3-carboxami de (29 mg, 0.077 mmol, 47%) as a white solid. 1< H NMR (300 MHz, Chloroform-d) δ 8.38 - 8.21 (m, 2H), 8.06 (d, J = 9.7 Hz, 1H), 7.63 - 7.50 (m, 1H), 7.28 (s, 2H), 7.05 (d, J = 9.7 Hz, 1H), 6.97 (t, J = 8.1 Hz, 3H), 4.13 (d, J = 7.3 Hz, 2H), 3.99 (s, 2H), 1.43 (t, J = 8.0 Hz, 1H), 0.61 (d, J = 7.7 Hz, 2H), 0.50 (d, J = 5.1 Hz, 2H); LCMS (ESI) m / z: 379.3 [M+H] +< .Example 80. Preparation of 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (80)

[0297] Step 1: Preparation of 5-(3-fluorobenzyl)pyridin-2-amine

[0298]

[0299] To a solution of 1-(bromomethyl)-3-fluorobenzene (1.0 g, 5.32 mmol), 6-aminopyridin-3-ylboronic acid (0.734 g, 5.32 mmol), potassium carbonate (1.47 g, 10.6 mmol) in tetrahydrofuran (12 mL) and water (3 mL) under nitrogen was added tetrakis(triphenylphosphine)palladium(0) (0.614 g, 0.532 mmol). The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(3-fluorobenzyl)pyridin-2-amine as a yellow oil (0.55 g); LCMS (ESI) m / z: 203.1 [M+H] +< .Step 2: Preparation of 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide

[0300]

[0301] To a solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.150 g, 0.899 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (0.181 g, 0.899 mmol) in pyridine (4 mL) at 20 °C was added phosphorus(V) oxychloride (0.410 g, 2.70 mmol). The reaction mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure. The resulting solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0750 g, 0.216 mmol, 24%) as a light-yellow solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.65 (s, 1H), 8.64 (d, J = 2.5 Hz, 1H), 8.31 (d, J = 2.5 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.93-7.95 (m, 1H), 7.70-7.73 (m, 1H), 7.35 (d, J = 6.5 Hz, 1H), 7.04-7.13 (m, 3H), 6.43 (d, J = 9.5 Hz, 1H), 3.95-3.99 (m, 4H), 1.27 (t, J = 7.2Hz, 3H); LCMS (ESI) m / z: 352.1 [M+H] +< .Example 81. Preparation of 1-ethyl-N-(5-(4-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (81)

[0302] Step 1: Preparation of 5-(4-fluorobenzyl)pyridin-2-amine

[0303]

[0304] To a solution of 1-(bromomethyl)-4-fluorobenzene (1.0 g, 5.32 mmol), 6-aminopyridin-3-ylboronic acid (0.735 g, 5.32 mmol), potassium carbonate (1.47 g, 10.6 mmol) in tetrahydrofuran (12 mL) and water (3 mL) under nitrogen was added tetrakis(triphenylphosphine)palladium(0) (0.614 g, 0.532 mmol). The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(4-fluorobenzyl)pyridin-2-amine (0.35 g, crude)as a yellow oil. LCMS (ESI) m / z: 203.1 [M+H] +< . Used in the next step without further purification.Step 2: Preparation of 1-ethyl-N-(5-(4-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide

[0305]

[0306] To a solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.150 g, 0.899 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (0.181 g, 0.899 mmol) in pyridine (4 mL) at 20 °C was added, phosphorus(V) oxychloride (410 mg, 2.697 mmol). The reaction mixture was stirred at room temperature for 3 h. Volatiles were removed under reduced pressure and the solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give 1-ethyl-N-(5-(4-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide as a light-yellow solid (0.0340 g, 0.099 mmol, 11%). 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.59 (s, 1H), 8.64 (d, J = 2.5 Hz, 1H), 8.28 (d, J = 2 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.93-7.95 (m, 1H), 7.65-7.67 (m, 1H), 7.28-7.31 (m, 2H), 7.11-7.15 (m, 2H), 6.42 (d, J = 9.5 Hz, 1H), 3.94-3.99 (m, 4H), 1.27 (t, J = 7.0 Hz, 3H); LCMS (ESI) m / z: 352.1 [M+H] +< .Example 82. Preparation of N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (82)

[0307] Step 1: Preparation of N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0308]

[0309] To a solution of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.2 g, 0.85 mmol), 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.17 g, 1.02 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.39 g, 1.02 mmol) in N,N-dimethylformamide (3 mL) was added triethylamine (0.26 g, 2.53 mmol). The mixture was stirred at 90 °C for 2 h and then cooled to room temperature. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0733 g, 0.19 mmol, 22.4%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.68 (s, 1H), 8.64 (d, J = 2.6 Hz, 1H), 8.32 (d, J = 2.6 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.94 (dd, J = 8.5, 2.6 Hz, 1H), 7.73 (dd, J = 8.5, 2.6 Hz, 1H), 7.52 (dd, J = 7.2, 2.1 Hz, 1H), 7.40 - 7.23 (m, 2H), 6.43 (d, J = 9.5 Hz, 1H), 4.03 - 3.90 (m, 4H), 1.28 (t, J = 7.1 Hz, 3H); LCMS (ESI) m / z: 386.0 [M+H] +< .Example 83. Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxamide (83)

[0310] Step 1: Preparation of methyl 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate

[0311]

[0312] A mixture of methyl 6-hydroxynicotinate (10.0 g, 65.3 mmol), 2-iodopropane (11.1 g, 65.3 mmol), potassium carbonate (18.0 g, 130.6 mmol) in acetonitrile (450 mL) was stirred at 80 °C for 16 h. The precipitate was filtered and the filtrate was concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 4 / 1 to 1 / 1) to give methyl 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate (6.5 g, 33.3 mmol, 51%) as a white solid. 1< H NMR (500 MHz, Chloroform-d) δ 8.23 (d, J = 3.0 Hz, 1H), 7.82 (dd, J = 9.0, 3.0 Hz, 1H), 6.54 (d, J = 9.0 Hz, 1H), 5.28-5.23 (m, 1H), 3.88 (s, 3H), 1.41 (d, J = 6.5 Hz, 6H); LCMS (ESI) m / z: 196.2 [M+H] +< .Step 2: Preparation of 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid

[0313]

[0314] A mixture of methyl 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate (4.0 g, 20.5 mmol), lithium hydroxide hydrate (4.3 g, 102.5 mmol) in tetrahydrofuran (100 mL) and water (25 mL) was stirred at room temperature for 2 h. The reaction solution was acidified to pH 1-2 with dilute hydrochloric acid and the aqueous layer was extracted with ethyl acetate / tetrahydrofuran (200 mL / 50 mL x 3). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (3.5 g, 19.3 mmol, 94.3%) as an off-white solid. LCMS (ESI) m / z: 182.2 [M+H] +< . Used in the next step directly without additional purification.Step 3: Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0315]

[0316] A mixture of 5-(3-chlorobenzyl)pyridin-2-amine(218 mg, 1.0 mmol), 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (181 mg, 1.0 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (570 mg, 1.5 mmol), N-N,N-diisopropylethyl amine (390 mg, 3.0 mmol) in N,N-dimethylformamide (10 mL) was stirred at room temperature for 0.5 h and at 90 °C for 2 h. The mixture was poured into water and the aqueous layer was extracted with ethyl acetate (150 mL x 2). The combined organic phases were concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) and prep-HPLC (the crude sample was dissolved in minimal N-N,N-dimethylformamide and loaded onto Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to afford

[0317] N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.056 g, 0.15 mmol, 14.6%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.83 (s, 1H), 8.58 (d, J = 2.5 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.92 (dd, J = 9.0, 2.5 Hz, 1H), 7.69 (dd, J = 9.0, 2.5 Hz, 1H), 7.36-7.33 (m, 2H), 7.28-7.23 (m, 2H), 6.44 (d, J = 9.5 Hz, 1H), 5.09-5.03 (m, 1H), 3.97 (s, 2H), 1.37 (d, J = 7.0 Hz, 6H); LCMS (ESI) m / z: 382.1 [M+H] +< .Example 84. Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (84)

[0318] Step 1: Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0319]

[0320] A solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.60 mmol), 5-(3-chlorobenzyl)pyridin-2-amine (0.157 g, 0.72 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.342 g, 0.9 mmol) and N,N-diisopropylethylamine (0.232 g, 1.8 mmol) in N,N-dimethylformamide (3 mL) was stirred at 90 °C for 1 h. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide a white solid (0.056 g, 0.153 mmol, 25.5%). 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.70 (s, 1H), 8.65 (d, J = 2.5 Hz, 1H), 8.32 (d, J = 1.8 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.95 (dd, J = 9.5, 2.5 Hz, 1H), 7.73 (dd, J = 8.6, 2.1 Hz, 1H), 7.34-7.32 (m, 2H), 7.28-7.23 (m, 2H), 6.44 (d, J = 9.5 Hz, 1H), 3.99 - 3.95 (m, 4H), 1.28 (t, J = 7.1 Hz, 3H); LCMS (ESI) m / z: 368.0 [M+H] +< .Example 85. Preparation of 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (85)

[0321] Step 1: Preparation of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate

[0322]

[0323] A mixture of methyl 6-hydroxynicotinate (15.3 g, 100 mmol), potassium carbonate (27.6 g, 200 mmol) in N,N-dimethylformamide (150 mL) was stirred at room temperature for 10 minutes, before iodoethane (17.2 g, 110 mmol) was added. The reaction mixture was stirred at room temperature for another 4 h and quenched with water (500 mL) and extracted with ethyl acetate (400 mL x 3). The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated. The reside was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 9 / 1 to 1 / 1) to afford methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (6.0 g, contained residual N,N-dimethylformamide) as an orange oil. 1< H NMR (500 MHz, Chloroform-d) δ 8.22 (d, J = 3.0 Hz, 1H), 7.83 (dd, J = 12.0, 3.5 Hz, 1H), 6.52 (d, J = 12.0 Hz, 1H), 4.04 (q, J = 9.0 Hz, 2H), 3.86(s, 3H), 1.38 (t, J = 9.0 Hz, 3H); LCMS (ESI) 182.1 [M+H] +< .Step 2: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid

[0324]

[0325] A mixture of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (5.8 g, 32.0 mmol), lithium hydroxide (6.72 g, 160.0 mmol) in tetrahydrofuran (60 mL) and water (15 mL) was stirred at room temperature for 2 h. The organics were removed under reduced pressure. The water phase was acidified to pH = 1-2 with dilute aqueous hydrogen chloride and extracted with 2-methylfuran (200 mL x 3). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (2.8 g, 52.3%) as a light-yellow solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 12.80 (bs, 1H), 8.47 (d, J = 2.5 Hz, 1H), 7.77 (dd, J = 9.5, 2.5 Hz, 1H), 6.40 (d, J = 9.5 Hz, 1H), 3.99 (q, J = 7.0 Hz, 2H), 1.23 (d, J = 7.0 Hz, 3H); LCMS (ESI) m / z: 168.1 [M+H] +< .Step 3: Preparation of 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide

[0326]

[0327] A mixture of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.098 g, 0.59 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (0.120 g, 0.59 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.342 g, 0.900 mmol) and N,N-diisopropylethylamine (0.155 g, 1.2 mmol) in N,N-dimethylformamide (3 mL) was stirred at room temperature for 1 h and then at 90 °C for 1 h. The mixture was poured into water and extracted with ethyl acetate (50 mL x 3). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 4) and then by prep-HPLC twice (first by: sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid). Second by: sample was dissolved in minimal N,N-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to afford compound 1-ethyl-N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0179 g, 0.0507 mmol, 8.6%) as a grey solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.65 (s, 1H), 8.65 (d, J = 2.5 Hz, 1H), 8.31 (d, J = 2.5 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.94 (dd, J = 9.5, 3.0 Hz, 1H), 7.71 (dd, J = 8.5, 2.0 Hz, 1H), 7.35 (dd, J = 14.0, 8.5 Hz, 1H), 7.13-7.10 (m, 2H), 7.04 (td, J = 8.5, 2.0 Hz, 1H), 6.43 (d, J = 9.5 Hz, 1H), 3.99-3.95 (m, 4H), 1.28 (t, J = 7.5 Hz, 3H); LCMS (ESI) m / z: 352.2 [M+H] +< .Example 108. Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxamide (108)

[0328] Step 1: Preparation of methyl 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylate

[0329]

[0330] A solution of methyl 5-oxo-4,5-dihydropyrazine-2-carboxylate (1.00 g, 6.5 mmol), iodomethane (0.767 g, 5.4 mmol) and potassium carbonate (1.49 g, 10.8 mmol) in acetonitrile (27 mL) was stirred at 85 °C for 4 h. The reaction mixture was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) gives methyl 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylate (0.480 g, 2.97 mmol, 45.7%) as a white solid. LCMS (ESI) m / z: 169.1 [M+H] +< .Step 2: Preparation of 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylic acid

[0331]

[0332] To a solution of methyl 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylate (0.430 g, 2.56 mmol) in methanol (9 mL) and water (3 mL) was added sodium hydroxide (0.205 g, 5.12 mmol). The reaction mixture was stirred at room temperature for 1 h before aqueous 1 N hydrogen chloride was added and the pH was adjusted to 6. Concentration under reduced pressure gives 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylic acid (0.660 g, crude) as a white solid. LCMS (ESI) m / z: 155.1 [M+H] +< .Step 3: Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxamide

[0333]

[0334] A solution of 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylic acid (0.154 g, 1.0 mmol), 5-(3-chlorobenzyl)pyridin-2-amine (0.260 g, 1.2 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.570 g, 1.5 mmol) and N,N-diisopropylethylamine (0.387 g, 3 mmol) in N,N-dimethylformamide (4 mL) was stirred at room temperature for 2 h and then at 90 °C for 1 h. The reaction mixture was cooled to room temperature and the resulting precipitate was filtered and washed with water. Freeze drying yields N-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxamide (0.0756 g, 0.214 mmol, 21.4%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 9.78 (s, 1H), 8.61 (s, 1H), 8.30 (d, J = 1.5 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.04 (s, 1H), 7.75 (dd, J = 8.4, 2.0 Hz, 1H), 7.35 - 7.32 (m, 2H), 7.28-7.23 (m, 2H), 3.97 (s, 2H), 3.55 (s, 3H); LCMS (ESI) m / z: 355.1 [M+H] +< .Example 117. Preparation of 5-fluoro-N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (117)

[0335] Step 1: Preparation of 5-fluoro-N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0336]

[0337] To a solution of 5-(3-fluorobenzyl)pyridin-2-amine (300 mg, 1.48 mmol) in 1,4-dioxane (6 mL) was added trimethylaluminum (0.72 mL, 1.44 mmol, 2 M in toluene) slowly at room temperature under argon. The mixture was stirred at room temperature for 30 minutes before methyl 5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (67 mg, 0.36 mmol) in 1,4-dioxane (2 mL) was added. The resulting mixture was heated to 100 °C and stirred for 16 h. The reaction solution was cooled to room temperature and was quenched with hydrochloric acid (0.5 N, 25 mL) and ethyl acetate (50 mL). The organic was washed with hydrochloric acid (0.5 N, 25 mL x 2), and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, ethyl acetate / petroleum ether = 2 / 1). The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give 5-fluoro-N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (70 mg, 0.20 mmol, 54.8%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.66 (s, 1H), 8.57 (s, 1H), 8.32 (d, J = 1.8 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.96 (dd, J = 11.0, 2.2 Hz, 1H), 7.73 (dd, J = 8.6, 2.2 Hz, 1H), 7.35 (d, J = 6.4 Hz, 1H), 7.21 - 7.08 (m, 2H), 7.04 (s, 1H), 3.98 (s, 2H), 3.58 (s, 3H); LCMS (ESI) m / z: 356.0 [M+H] +< .Example 127. Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (127)

[0338] Step 1: Preparation of methyl 5-bromo-6-oxo-1,6-dihydropyridazine-3-carboxylate

[0339]

[0340] To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (9.0 g, 58.4 mmol) in acetic acid (100 mL) at room temperature was added potassium acetate (17.2 g, 175 mmol) and bromine (18.66 g, 117 mmol). The resulting solution was stirred for 6 h at 80 °C. The reaction mixture was quenched with aqueous sodium bisulfate solution (100 mL, 3 mol / L). The aqueous layer was extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated to yield methyl 5-bromo-6-oxo-1,6-dihydropyridazine-3-car-boxylate (11.1 g, 47.9 mmol, 82%, crude) as a light-yellow solid. LCMS (ESI) m / z: 233.0 [M+H] +< . Used in the next step directly without additional purification.Step 2: Preparation of methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate

[0341]

[0342] To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (2.0 g, 8.58 mmol), potassium carbonate (2.38 g, 17.16 mmol) in N,N'-dimethylformamide (10.0 mL) was added 1-iodomethane (0.73 g, 5.15 mmol). The reaction mixture was stirred at room temperature for 3 h. The solution was dissolved in the ethyl acetate (50 mL). The combined organic layers were separated, washed with water (50 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) to offer methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (1.60 g, 6.50 mmol, 76.2%) as a white solid. LCMS (ESI) m / z: 247.0 [M+H] +< .Step 3: Preparation of 5-methoxy-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

[0343]

[0344] To a solution of methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (300 mg, 1.22 mmol) in methanol (4.0 mL), tetrahydrofuran (4.0 mL) and water (1.0 mL) mixture was added lithium hydroxide hydrate (102 mg, 2.44 mmol). The reaction solution was stirred at room temperature for 1 h before 1 N aqueous hydrochloric acid was added to adjust the pH value to 3~5. The volatiles were removed to give 5-methoxy-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (200 mg, 1.09 mmol, 89%, crude) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 13.66 (s, 1H), 8.26 (s, 1H), 3.88 (s, 3H), 3.78 (s, 3H); LCMS (ESI) m / z: 185.1 [M+H] +< . Used in the next step directly without additional purification.Step 4: Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-5-methoxy-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0345]

[0346] To a solution of 5-methoxy-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (121 mg, 0.659 mmol) and diisopropylethylamine (255 mg, 1.98 mmol) in tetrahydrofuran (5.0 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (376 mg, 0.659 mmol). The reaction solution was stirred for 20 minutes before a solution of 5-(3-fluorobenzyl)pyridin-2-amine (144 mg, 0.659 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction mixture was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the crude material was added to a mixture of dichloromethane (50 mL) and water (50 mL). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile / 0.01% aqueous trifluoroacetic acid) to give N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide (43.0 mg, 0.117 mmol, 22%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.05 (s, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.3 Hz, 1H), 7.34 (dd, J = 14.3, 8.0 Hz, 1H), 7.26 (s, 1H), 7.11 (t, J = 7.7 Hz, 2H), 7.04 (t, J = 7.4 Hz, 1H), 3.99 (s, 2H), 3.93 (s, 3H), 3.78 (s, 3H); LCMS (ESI) m / z: 369.1 [M+H] +< .Example 128. Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (128)

[0347] Step 1: Preparation of 3-fluoro-5-(methoxycarbonyl)pyridine 1-oxide

[0348]

[0349] To a solution of methyl 5-fluoronicotinate (3.54 g, 22.8 mmol) and urea hydrogen peroxide (4.64 g, 47.88 mmol) in dichloromethane (50 mL) at 0 °C was added trifluoroacetic anhydride (6.4 mL, 118 mmol) dropwise under nitrogen. The reaction mixture was stirred at room temperature for 17 h. The reaction vessel was cooled to 0 °C and saturated aqueous sodium bisulfate was added. The aqueous layer extracted with dichloromethane (100 mL x 3). The combined organic layers were washed with saturated aqueous sodium bisulfate (50 mL), dried over sodium sulfate, filtered and concentrated to give 3-fluoro-5-(methoxycarbonyl)pyridine 1-oxide as a light-yellow solid (3.78 g, 22.1 mmol, 97 %); LCMS (ESI) m / z: 172.1 [M+H] +< .Step 2: Preparation of methyl 5-fluoro-6-oxo-1,6-dihydropyridine-3-carboxylate

[0350]

[0351] 3-fluoro-5-(methoxycarbonyl)pyridine1-oxide (2.5 g, 14.6 mmol) in acetic anhydride (75 mL) was stirred at 140 °C for 5 h under nitrogen. The reaction was cooled to room temperature and was concentrated. The residue was heated to 50 °C for 15 minutes and concentrated. The crude brown solid was suspended in dichloromethane and filtered, the product was then dried in vacuo to give methyl 5-fluoro-6-oxo-1,6-dihydropyridine-3-carboxylate as a yellow solid (880 mg, 5.15 mmol, 35%); LCMS (ESI) m / z: 172.1 [M+H] +< .Step 3: Preparation of methyl 5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate

[0352]

[0353] To a solution of methyl 5-fluoro-6-oxo-1,6-dihydropyridine-3-carboxylate (838 mg, 4.9 mmol) and potassium carbonate (1.36 g, 9.8 mmol) in N,N-dimethylformamide (20 mL) was added iodomethane (1.04 g, 7.35 mmol) at room temperature under nitrogen. The mixture was stirred at room temperature for 2 h. The volatiles were removed in vacuo and the crude product was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) to give methyl 5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate as a yellow solid (830 mg, 4.5 mmol, 91 %); LCMS (ESI) m / z: 186.1 [M+H] +< .Step 4: Preparation of N-(5-(3-chlorobenzyl)pyridin-2-yl)-5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0354]

[0355] To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (323 mg, 1.48 mmol) in 1,4-dioxane (6 mL) at room temperature was added trimethylaluminum (0.72 mL, 1.44 mmol, 2 M in toluene) slowly under argon. The mixture was stirred at room temperature for 30 minutes before methyl 5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (67 mg, 0.36 mmol) in 1,4-dioxane (2 mL) was added. The resulting solution was heated to 100 °C and stirred for 16 h. The reaction mixture was cooled to room temperature and was quenched with hydrochloric acid (0.5 N, 25 mL) and ethyl acetate (50 mL). The combined organic layers were washed with hydrochloric acid (0.5 N, 25 mL x 2) and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified first by column chromatography (silica gel, ethyl acetate / petroleum ether= 2 / 1) and by prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to offer N-(5-(3-chlorobenzyl)pyridin-2-yl)-5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (70 mg, 0.19 mmol, 52.4%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.66 (s, 1H), 8.57 (d, J = 1.7 Hz, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.96 (dd, J = 11.0, 2.3 Hz, 1H), 7.73 (dd, J = 8.6, 2.3 Hz, 1H), 7.37 - 7.31 (m, 2H), 7.30 - 7.18 (m, 2H), 3.97 (s, 2H), 3.58 (s, 3H); LCMS (ESI) m / z: 372.0 [M+H] +< .Example 140. Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (140)

[0356] Step 1: Preparation of N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

[0357]

[0358] To a mixture of 1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (100 mg, 0.653 mmol), and diisopropylethylamine (253 mg, 1.959 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (372 mg, 0.98 mmol). The reaction solution was stirred for 20 minutes before a solution of 5-(3-fluorobenzyl)pyridin-2-amine (132 mg, 0.653 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction mixture was stirred at 20 °C for 4 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, dichloromethane / methanol = 20 / 1) to offer N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (89.6 mg, 0.27 mmol, 41%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 12.48 (s, 1H), 8.45-8.47 (m, 1H), 8.29 (s, 1H), 8.21 (s, 1H), 8.17-8.19 (m, 1H), 7.69-7.72 (m, 1H), 7.35 (q, J = 6.6 Hz, 1H), 7.10-7.13 (m, 2H), 7.03 (t, J = 8.0 Hz, 1H), 6.60 (t, J = 8.0 Hz, 1H), 3.96 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m / z: 338.0 [M+H] +< .Example 171. Preparation of N-(5-(3-chlorobenzyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (171)

[0359] Step 1: Preparation of N-(5-(3-chlorobenzyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0360]

[0361] A suspension of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.245 g, 1.6 mmol), 2-chloro-5-(3-chlorobenzyloxy) pyridine (0.202 g, 0.8 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.073 g, 0.08 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.046 g, 0.08 mmol) and cesium carbonate (0.522 g, 1.6 mmol) in 1.4-dioxane (6 mL) was stirred at 90 ° C for 6 h under argon. The reaction mixture was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was washed with methanol / acetonitrile = 1 / 2 (4.5 mL) to give N-(5-(3-chlorobenzyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0574 g, 0.16 mmol, 19.4%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.10 (s, 1H), 8.19 (d, J = 1.6 Hz, 1H), 8.07 (d, J = 9.2 Hz, 1H), 7.94 (d, J = 9.6 Hz, 1H), 7.60 (dd, J = 8.8, 3.2 Hz, 1H), 7.55 (s, 1H), 7.45 - 7.41 (m, 3H), 7.07 (d, J = 9.2 Hz, 1H), 5.20 (s, 2H), 3.79 (s, 3H) ); LCMS (ESI) m / z: 371.0 [M+H] +< .Example 172. Preparation of N-(5-(3-chlorobenzyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (172)

[0362] Step 1: Preparation of N-(5-((3-chlorophenoxy)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0363]

[0364] A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.243 g, 1.6 mmol), 2-chloro-5-((3-chlorophenoxy)methyl) pyridine (0.202 g, 0.8 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.073 g, 0.08 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.046 g, 0.08 mmol) and cesium carbonate (0.522 g, 1.6 mmol) in 1,4-dioxane (6 mL) was stirred at 90 ° C for 3 h under argon. The reaction mixture was extracted with ethyl acetate (100 mL x 2). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, dichloromethane / methanol = 50 / 1) to give N-(5-((3-chlorophenoxy)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0565 g, 0.15 mmol, 19.2%) as a pink solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 10.65 (s, 1H), 8.69 (d, J = 2.5 Hz, 1H), 8.47 (d, J = 1.5 Hz, 1H), 8.17 (d, J = 8.0 Hz, 1H), 7.99 (dd, J = 9.5, 2.5 Hz, 1H), 7.91 (dd, J = 8.5, 2.0 Hz, 1H), 7.33 (t, J = 8.0 Hz, 1H), 7.14 (t, J = 1.8 Hz, 1H), 7.03 - 7.00 (m, 2H), 6.44 (d, J = 9.5 Hz, 1H), 5.14 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m / z: 370.1 [M+H] +< .Example 173. Preparation of N-(5-((3-Chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamid e (173)

[0365] Step 1: Preparation of N-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

[0366]

[0367] To a solution of 3-chloro-N-((6-chloropyridin-3-yl)methyl)aniline (0.130g, 0.51 mmol) in anhydrous 1,4-dioxane (15 mL) at room temperature was added 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.078 g, 0.51 mmol), tris(dibenzylideneacetone)dipalladium(0) (24 mg, 0.03 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.030 g, 0.05 mmol) and cesium carbonate (0.251 g, 0.77 mmol) under nitrogen. The reaction mixture was stirred at 90 °C for 5 h, cooled to room temperature and diluted with water (100 mL). The aqueous layer was extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to give N-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.127 g, 0.34 mmol, 67%) as a white solid. 1< H NMR (400 MHz, Dimethylsulfoxide-d 6 ) δ 10.54 (s, 1H), 8.67 (d, J = 2.4 Hz, 1H), 8.36 (d, J = 1.6 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.98 (dd, J 1 = 2.8 Hz, J 2 = 9.6 Hz, 1H), 7.78 (dd, J 1 = 2.0 Hz, J 2 = 8.4 Hz, 1H), 7.06 (t, J = 8.0 Hz, 1H), 6.61 (t, J = 2.0 Hz, 1H), 6.57-6.52 (m, 3H), 6.43 (d, J = 9.6 Hz, 1H), 4.27 (d, J = 5.6 Hz, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 369.1 [M+H] +< .Example 174. Preparation of N-(5-((3-Chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxa mide (174)

[0368] Step 1: Preparation of 3-chloro-N-((6-chloropyridin-3-yl)methyl)aniline

[0369]

[0370] To a solution of 3-chloroaniline (3.0 g, 23.5 mmol) in ethanol (60 mL) at room temperature was added 6-chloronicotinaldehyde (3.33 g, 23.5 mmol), acetic acid (0.141 g, 2.35 mmol) and sodium cyanoborohydride (4.43 g, 70.55 mmol). The reaction mixture was stirred at 50 °C for 5 h before it was cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The cruse product was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 1 / 1) to afford 3-chloro-N-((6-chloropyridin-3-yl)methyl)aniline (4.5 g, 17.8 mmol, 75%) as a white solid. LCMS (ESI) m / z: 254.1 [M+H] +< .Step 2: Preparation of N-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

[0371]

[0372] To a solution of 3-chloro-N-((6-chloropyridin-3-yl)methyl)aniline (0.100 g, 0.40 mmol) in anhydrous 1,4-dioxane (12 mL) at room temperature was added 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.061 g, 0.40 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.018 g, 0.02 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.024.0 g, 0.04 mmol) and cesium carbonate (0.194 g, 0.60 mmol) under nitrogen. The reaction mixture was stirred at 90 °C for 5 h before it was cooled to room temperature and diluted with water (100 mL). The aqueous layer was extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal N,N-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile / 10 mM ammonium acetate aqueous solution) to give N-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.105 g, 0.28 mmol, 71%) as a white solid. 1< H NMR (500 MHz, Dimethylsulfoxide-d 6 ) δ 8.38 (d, J = 1.5 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 9.5 Hz, 1H), 7.84 (dd, J 1 = 2.5 Hz, J 2 = 8.5 Hz, 1H), 7.09-7.04 (m, 2H), 6.61-6.53 (m, 4H), 4.29 (d, J = 5.5 Hz, 2H), 3.79 (s, 3H); LCMS (ESI) m / z: 370.0 [M+H] +< .Example 238. Characterization Data of Compounds of the Invention and reference compounds

[0373] The following compounds were synthesized by methods similar to those described above.

[0374] Compound 240: 1< H NMR (300 MHz, DMSO-d6) δ 10.93 (s, 1H), 8.33 (dd, J = 2.5, 0.8 Hz, 1H), 8.04 (dd, J = 8.5, 0.8 Hz, 1H), 7.81 (d, J = 7.0 Hz, 1H), 7.72 (dd, J = 8.5, 2.4 Hz, 1H), 7.34 (td, J = 8.0, 6.3 Hz, 1H), 7.27 - 6.96 (m, 4H), 6.93 (dd, J = 2.0, 0.6 Hz, 1H), 6.60 (dd, J = 7.0, 2.0 Hz, 1H), 3.98 (s, 2H), 3.45 (s, 3H); LCMS (ESI) m / z: 338.4 [M+H]+.

[0375] Compound 248: 1< H NMR (400 MHz, Dimethylsulfoxide-d6) δ 10.62 (s, 1H), 8.67 (s, 1H), 8.29 (s, 1H), 8.02 (d, J = 8 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.30 (t, J = 6 Hz, 2H), 7.12 (t, J = 8.3 Hz, 2H), 6.44 (t, J = 9.5 Hz, 2H), 3.95 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 338.1 [M+H]+.

[0376] Compound 251: 1< H NMR (500 MHz, DMSO-d6) δ 10.05 (s, 1H), 8.33 (s, 1H), 8.08 - 8.06 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.75 - 7.72 (d, J = 8.6 Hz, 1H), 7.43 - 7.26 (m, 1H), 7.12 - 7.10 (t, J = 7.2 Hz, 2H), 7.04 - 7.01 (t, J = 8.6 Hz, 1H), 3.99 (s, 2H), 3.79 (s, 3H), 2.17 (s, 3H); LCMS (ESI) m / z: 353.0 [M+H]+.

[0377] Compound 256: 1< H NMR (500 MHz, DMSO-d6) δ 10.10 (s, 1H), 8.34-8.35 (d, J = 2.0 Hz, 1H), 8.04-8.06 (d, J = 8.5 Hz, 1H), 7.89-7.91 (d, J = 10.0 Hz, 1H), 7.73-7.75 (m, 1H), 7.32-7.34 (m, 2H), 7.22-7.28 (m, 2H), 7.05-7.07 (m, 1H), 4.08-4.09 (t, J = 3.5 Hz, 1H), 3.98 (s, 2H); LCMS (ESI) m / z: 381.1 [M+H]+.

[0378] Compound 258: 1< H NMR (500 MHz, DMSO-d6) δ 10.84 (s, 1H), 8.40-8.41 (d, J = 2.5 Hz, 1H), 8.31 (d, J = 1.5 Hz, 1H), 8.02-8.03 (d, J = 8.5 Hz, 1H), 7.89-7.91 (m, 1H), 7.71-7.73 (m, 1H), 7.32-7.36 (m, 2H), 7.10-7.12 (m, 2H), 7.03 (m, 1H), 6.42-6.46 (d, J = 10.0 Hz, 1H), 3.97 (s, 2H), 3.39 (m, 1H); LCMS (ESI) m / z: 364.1 [M+H]+.

[0379] Compound 262: 1< H NMR (500 MHz, DMSO-d6) δ 10.24 (s, 1H), 8.49 (d, J = 1.8 Hz, 1H), 8.20 (d, J = 8.5 Hz, 1H), 8.03 - 7.90 (m, 2H), 7.33 (t, J = 8.2 Hz, 1H), 7.17 - 6.98 (m, 4H), 5.16 (s, 2H), 3.80 (s, 3H); LCMS (ESI) m / z: 371.1 [M+H]+.

[0380] Compound 263: 1< H NMR (500 MHz, DMSO-d6) δ 10.63 (s, 1H), 8.69 (d, J = 2.6 Hz, 1H), 8.47 (d, J = 1.9 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 7.95 (ddd, J = 10.9, 9.0, 2.5 Hz, 2H), 7.33 (t, J = 8.2 Hz, 1H), 7.14 (t, J = 2.1 Hz, 1H), 7.06 - 6.97 (m, 2H), 6.44 (d, J = 9.5 Hz, 1H), 5.14 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m / z: 370.0 [M+H]+.

[0381] Compound 264: 1< H NMR (400 MHz, DMSO-d6) δ 10.72 (s, 1H), 8.67 (d, J = 2.4 Hz, 1H), 8.47 (d, J = 1.6 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.95 (dd, J = 9.6, 2.8 Hz, 1H), 7.91 (dd, J = 8.8, 2.4 Hz, 1H), 7.33 (t, J = 8.2 Hz, 1H), 7.14 (t, J = 4.0 Hz, 1H), 7.04-7.00 (m, 2H), 6.43 (d, J = 9.6 Hz, 1H), 5.14 (s, 2H), 4.01-3.95 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H); LCMS (ESI) m / z: 384.1 [M+H]+.

[0382] Compound 266: 1< H NMR (500 MHz, DMSO-d6) δ 10.64 (s, 1H), 8.69 (d, J = 2.7 Hz, 1H), 8.46 (d, J = 2.3 Hz, 1H), 8.16 (d, J = 8.6 Hz, 1H), 7.99 (dd, J = 9.5, 2.7 Hz, 1H), 7.91 (dd, J = 8.6, 2.4 Hz, 1H), 7.36 (t, J = 9.1 Hz, 1H), 7.30 (dd, J = 6.1, 3.1 Hz, 1H), 7.09 - 7.01 (m, 1H), 6.44 (d, J = 9.5 Hz, 1H), 5.12 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m / z: 388.0 [M+H]+.

[0383] Compound 272: 1< H NMR (400 MHz, DMSO-d6) δ 10.90 (s, 1H), 8.64 (d, J = 2.4 Hz, 1H), 8.32 (d, J = 1.9 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.96 (dd, J = 9.6, 2.5 Hz, 1H), 7.70 (dd, J = 8.6, 2.1 Hz, 1H), 7.35 (d, J = 6.4 Hz, 1H), 7.10 (dd, J = 21.8, 15.3 Hz, 3H), 6.46 (d, J = 9.5 Hz, 1H), 5.55 (d, J = 7.4 Hz, 1H), 4.89 (d, J = 7.2 Hz, 4H), 3.98 (s, 2H); LCMS (ESI) m / z: 380.0 [M+H]+.

[0384] Compound 273: 1< H NMR (400 MHz, DMSO-d6) δ 10.90 (s, 1H), 8.64 (d, J = 2.4 Hz, 1H), 8.32 (d, J = 1.9 Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H), 7.96 (dd, J = 9.6, 2.5 Hz, 1H), 7.70 (dd, J = 8.6, 2.3 Hz, 1H), 7.30 (ddd, J = 22.2, 10.8, 5.7 Hz, 4H), 6.46 (d, J = 9.6 Hz, 1H), 5.67 - 5.46 (m, 1H), 4.89 (d, J = 7.2 Hz, 4H), 3.97 (s, 2H); LCMS (ESI) m / z: 396.1 [M+H]+.

[0385] Compound 280: 1< H NMR (500 MHz, DMSO-d6) δ 10.22 (s, 1H), 8.36 (s, 1H), 8.34 - 8.31 (d, J = 1.9 Hz, 1H), 8.07-8.06 (d, J = 8.5 Hz, 1H), 7.76-7.74 (m, 1H), 7.35-7.33 (m, 1H), 7.12-7.10 (t, J = 7.9 Hz, 2H), 7.04-7.01 (m, 5.2 Hz, 1H), 3.99 (s, 2H), 3.85 (s, 3H); LCMS (ESI) m / z: 416.9 [M+H]+.

[0386] Compound 282: 1< H NMR (500 MHz, DMSO-d6) δ 10.13 (s, 1H), 8.34 (d, J = 2.0 Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 10.0 Hz, 1H), 7.76 (dd, J = 8.5, 2.5 Hz, 1H), 7.08 (d, J = 9.5 Hz, 1H), 6.91 (s, 1H), 6.87-6.85 (m, 2H), 3.93 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H); LCMS (ESI) m / z: 385.1 [M+H]+.

[0387] Compound 286: 1< H NMR (500 MHz, DMSO-d6) δ 10.14 (s, 1H), 7.93 (d, J = 9.7 Hz, 1H), 7.80 (dd, J = 38.0, 5.9 Hz, 2H), 7.44 (s, 1H), 7.35 (ddd, J = 22.5, 15.0, 7.5 Hz, 3H), 7.20 (dd, J = 8.8, 2.0 Hz, 1H), 7.07 (d, J = 9.7 Hz, 1H), 4.35 (s, 2H), 3.77 (s, 3H); LCMS (ESI) m / z: 370.0 [M+H]+.

[0388] Compound 287: 1< H NMR (500 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.71 (d, J = 2.5 Hz, 1H), 8.33 (d, J = 2.3 Hz, 1H), 8.10 - 8.02 (m, 2H), 7.89 (t, J = 59.4 Hz, 1H), 7.71 (dd, J = 8.5, 2.4 Hz, 1H), 7.40-7.29 (m, 1H), 7.15 - 7.08 (m, 2H), 7.06 - 6.99 (m, 1H), 6.61 (d, J = 9.8 Hz, 1H), 3.98 (s, 2H); LCMS (ESI) m / z: 374.1 [M+H]+.

[0389] Compound 291: 1< H NMR (500 MHz, DMSO-d6) δ 10.89 (s, 1H), 8.42-8.46 (m, 2H), 8.14-8.16 (d, J = 10.5 Hz, 1H), 7.88-7.92 (m, 2H), 7.34-7.38 (m, 1H), 7.30-7.34 (m, 1H), 7.13 (m, 1H), 6.99-7.02 (m, 2H), 6.41-6.43 (d, J = 12.0 Hz, 1H), 5.12 (s, 2H), 3.35-3.39 (m, 1H), 1.00-1.02 (d, J = 7.5 Hz, 4H); LCMS (ESI) m / z: 396.1 [M+H]+.

[0390] Compound 298: 1< H NMR (500 MHz, MeOD) δ 8.61 (s, 1H), 8.28 (s, 1H), 8.10 (dd, J = 9.5, 2.6 Hz, 1H), 8.04 (s, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.31 (t, J = 7.6 Hz, 2H), 7.25 - 7.15 (m, 3H), 6.63 (d, J = 9.5 Hz, 1H), 3.68 (s, 3H), 2.35 (t, J = 7.3 Hz, 2H), 1.70 - 1.51 (m, 2H); LCMS (ESI) m / z: 346.1 [M+H]+.

[0391] Compound 300: 1< H NMR (500 MHz, DMSO-d6) δ 10.12 (s, 1H), 8.58 (s, 1H), 8.19 (d, J = 2.5 Hz, 1H), 8.04 (d, J = 9.2 Hz, 1H), 7.95 (d, J = 10.0 Hz, 1H), 7.70 (dd, J = 8.5, 3.0 Hz, 1H), 7.28-7.23 (m, 1H), 7.08 (d, J = 10.0 Hz, 1H), 6.85 (dd, J = 8.1, 1.6 Hz, 1H), 6.80-6.77 (m, 1H), 6.63-6.60 (m, 1H), 3.79 (s, 3H); LCMS (ESI) m / z: 340.1 [M+H]+.

[0392] Compound 301: 1< H NMR (500 MHz, DMSO-d6) δ 10.20 (s, 1H), 8.25 (d, J = 2.0 Hz, 1H), 8.15 (d, J = 9.0 Hz, 1H), 7.96 (d, J = 9.5 Hz, 1H), 7.72 (dd, J = 9.0, 2.5 Hz, 1H), 7.25-7.23 (m, 1H), 7.08 (d, J = 10.0 Hz, 1H), 6.70 - 6.65 (m, 3H), 3.80 (s, 3H), 3.30 (s, 3H); LCMS (ESI) m / z: 354.1 [M+H]+.

[0393] Compound 302: 1< H NMR (500 MHz, DMSO-d6) δ 10.66 (s, 1H), 8.68 (d, J = 3.0 Hz, 1H), 8.23 (d, J = 2.5 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.00 (dd, J = 9.5, 2.5 Hz, 1H), 7.70 (dd, J = 9.5, 3.0 Hz, 1H), 7.26 - 7.21 (m, 1H), 6.68 - 6.61 (m, 3H), 6.44 (d, J = 9.5 Hz, 1H), 3.51 (s, 3H), 3.29 (s, 3H); LCMS (ESI) m / z: 353.0 [M+H]+.

[0394] Compound 303: 1< H NMR (500 MHz, DMSO-d6) δ 10.05 (s, 1H), 8.54 (s, 1H), 8.20 (d, J = 2.5 Hz, 1H), 8.04-8.06 (d, J = 9.0 Hz, 1H), 7.90-7.92 (d, J = 10.0 Hz, 1H), 7.65-7.68 (m, 1H), 7.22-7.26 (m, 1H), 7.05-7.07 (d, J = 9.0 Hz, 1H), 6.97-6.99 (m, 2H), 6.83-6.85 (m, 1H), 4.09-4.10 (m, 1H), 1.27-1.28 (m, 2H), 1.01-1.03 (m, 2H); LCMS (ESI) m / z: 382.0 [M+H]+.

[0395] Compound 304: 1< H NMR (500 MHz, DMSO-d6) δ 10.04 (s, 1H), 8.57 (s, 1H), 8.20-8.21 (d, J = 2.5 Hz, 1H), 8.04-8.06 (d, J = 8.5 Hz, 1H), 7.90-7.92 (d, J = 9.0 Hz, 1H), 7.66-7.69 (m, 1H), 7.24-7.26 (m, 1H), 7.05-7.07 (d, J = 9.5 Hz, 1H), 6.83-6.85 (d, J = 8.0 Hz, 1H), 6.76-6.78 (d, J = 11.5 Hz, 1H), 6.59-6.62 (m, 1H), 4.08-4.11 (m, 1H), 1.27-1.28 (m, 2H), 1.00-1.04 (m, 2H); LCMS (ESI) m / z: 366.1 [M+H]+.

[0396] Compound 328: 1< H NMR (500 MHz, DMSO-d6) δ 12.49 (s, 1H), 8.47 (d, J = 6.0 Hz, 1H), 8.29 (s, 1H), 8.20 (dd, J = 13.0, 7.5 Hz, 2H), 7.70 (d, J = 8.0 Hz, 1H), 7.36 ((dd, J = 19.0, 9.0 Hz, 2H), 7.12 (s, 1H), 6.60 (t, J = 7.0 Hz, 1H), 3.94 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m / z: 356.0 [M+H]+.

[0397] Compound 329: 1< H NMR (500 MHz, DMSO-d6) δ 12.49 (s, 1H), 8.47 (dd, J = 7.0, 2.0 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 8.22-8.17 (m, 2H), 7.73 (dd, J = 8.5, 2.0 Hz, 1H), 7.08-7.03 (m, 3H), 6.60 (t, J = 7.0 Hz, 1H), 3.97 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m / z: 327.1 [M+H]+.

[0398] Compound 330 : 1< H NMR (500 MHz, DMSO-d6) δ 12.48 (s, 1H), 8.46 (dd, J = 7.0, 2.0 Hz, 1H), 8.30 (d, J = 1.5 Hz, 1H), 8.22-8.17 (m, 2H), 7.71 (dd, J = 8.5, 2.0 Hz, 1H), 7.39 - 7.31 (m, 2H), 7.25 (dd, J = 16.0, 8.0 Hz, 2H), 6.60 (t, J = 7.0 Hz, 1H), 3.96 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m / z: 354.1 [M+H]+.

[0399] Compound 331: 1< H NMR (400 MHz, DMSO-d6) δ 12.49 (s, 1H), 8.46 (d, J = 6.4 Hz, 1H), 8.30 (s, 1H), 8.20 (t, J = 8.2 Hz, 2H), 7.71 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 6.8 Hz, 1H), 7.35 (t, J = 9.0 Hz, 1H), 7.30-7.27 (m, 1H), 6.60 (t, J = 6.8 Hz, 1H), 3.95 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m / z: 372.0 [M+H]+.

[0400] Compound 332: 1< H NMR (500 MHz, DMSO) δ 12.51 (s, 1H), 8.48-8.46 (m, 1H), 8.29 (s, 1H), 8.21 (d, J = 8.5 Hz, 2H), 7.72-7.70 (m, 1H), 7.35 (dd, J = 14.5, 7.5 Hz, 1H), 7.12 (t, J = 7.5 Hz, 2H), 7.04 (t, J = 8.5 Hz, 1H), 6.63 (t, J = 7.0 Hz, 1H), 4.12 (q, J = 7.0 Hz, 2H), 3.97 (s, 2H), 1.31 (t, J = 7.0 Hz, 3H); LCMS (ESI) m / z: 352.1 [M+H]+.

[0401] Compound 335: 1< H NMR (400 MHz, DMSO-d6) δ 10.16 (s, 1H), 8.54 (d, J = 6.4 Hz, 1H), 8.36 (s, 1H), 8.11 (d, J= 8.4 Hz, 1H), 7.72-7.84 (m, 1H), 7.28-7.42 (m, 1H), 6.92-7.18 (m, 4H), 3.99 (s, 2H), 3.54 (s, 3H); LCMS (ESI) m / z: 339.1 [M+H]+.

[0402] Compound 342: 1< H NMR (400 MHz, DMSO-d6) δ 10.52 (s, 1H), 8.66 (d, J = 2.3 Hz, 1H), 8.50 (s, 1H), 8.17 (d, J = 2.6 Hz, 1H), 8.10 - 7.95 (m, 2H), 7.65 (dd, J = 9.0, 2.7 Hz, 1H), 7.24 (t, J = 7.9 Hz, 1H), 6.96 (d, J = 8.1 Hz, 2H), 6.84 (d, J = 7.4 Hz, 1H), 6.44 (d, J = 9.5 Hz, 1H), 3.51 (s, 3H); LCMS (ESI) m / z: 355.0 [M+H]+.

[0403] Compound 349: 1< H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.53 (s, 1H), 8.18 (d, J = 2.8 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 8.00 (dd, J = 9.6, 2.8 Hz, 1H), 7.67 (dd, J = 9.2, 2.8 Hz, 1H), 7.28-7.22 (m, 1H), 6.83 (dd, J = 8.0, 1.2 Hz, 1H), 6.78-6.74 (m, 1H), 6.74-6.58 (m, 1H), 6.44 (d, J = 9.2 Hz, 1H), 3.51 (s, 3H); LCMS (ESI) m / z: 339.1 [M+H]+.

[0404] Compound 360: 1< H NMR (400 MHz, DMSO-d6) δ 10.17 (s, 1H), 8.35 (d, J = 1.9 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 9.7 Hz, 1H), 7.87 (dd, J = 8.5, 2.2 Hz, 1H), 7.28 (dt, J = 24.9, 12.5 Hz, 1H), 7.08 (d, J = 9.7 Hz, 1H), 6.90 - 6.65 (m, 3H), 4.23 (t, J = 6.6 Hz, 2H), 3.80 (s, 3H), 3.06 (t, J = 6.6 Hz, 2H); LCMS (ESI) m / z: 369.1 [M+H]+.

[0405] Compound 361: 1< H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H), 8.64 (d, J = 2.4 Hz, 1H), 8.17 (d, J = 2.8 Hz, 1H), 8.05 (d, J = 9.2 Hz, 1H), 7.98 (dd, J = 9.6, 2.4 Hz, 1H), 7.57-7.54 (m, 2H), 7.45 - 7.42 (m, 3H), 6.43 (d, J = 9.6 Hz, 1H), 5.20 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 370.1 [M+H]+.

[0406] Compound 365: 1< H NMR (500 MHz, DMSO-d6) δ 8.43-8.46 (m, 2H), 8.15-8.17 (d, J = 9.0 Hz, 1H), 7.89-7.92 (m, 2H), 7.34-7.38 (m, 1H), 7.30-7.31 (m, 1H), 7.03-7.06 (m, 1H), 5.12 (s, 2H), 3.37-3.41 (m, 1H), 1.02-1.03 (d, J = 5.5 Hz, 4H); LCMS (ESI) m / z: 414.0 [M+H]+.

[0407] Compound 367: 1< H NMR (400 MHz, DMSO-d6) δ 10.12 (s, 1H), 8.56 (s, 1H), 8.19 (d, J = 2.6 Hz, 1H), 8.09 (d, J = 8.9 Hz, 1H), 7.96 (d, J = 9.7 Hz, 1H), 7.69 (dd, J = 8.9, 2.8 Hz, 1H), 7.25 (t, J = 7.9 Hz, 1H), 7.09 (d, J = 9.7 Hz, 1H), 6.99 (d, J = 7.9 Hz, 2H), 6.85 (d, J = 7.1 Hz, 1H), 3.80 (s, 3H); LCMS (ESI) m / z: 356.0 [M+H]+.

[0408] Compound 411: 1< H NMR (300 MHz, Chloroform-d) δ 8.46 (s, 1H), 8.39 (s, 1H), 7.96 (d, J = 9.6 Hz, 1H), 7.67 (s, 1H), 7.46 (s, 1H), 7.31 (s, 5H), 7.04 - 6.90 (m, 3H), 6.87 (d, J = 9.6 Hz, 1H), 4.79 (d, J = 5.8 Hz, 2H), 4.03 (s, 2H), 3.87 (s, 3H); LCMS (ESI) m / z: 353.5 [M+H]+.

[0409] Compound 421: 1< H NMR (500 MHz, Dimethylsulfoxide-d6) δ 10.20 (s, 1H), 8.35 (s, 1H), 8.08 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 9.5 Hz, 1H), 7.76 (dd, J = 8.5, 2.0 Hz, 1H), 7.37-7.33 (m, 1H), 7.12-7.10 (m, 2H), 7.05-7.02 (m, 2H), 5.33-5.30 (m, 1H), 4.00 (s, 2H), 2.63-2.55 (m, 2H), 2.33-2.28 (m, 2H), 1.87-1.80 (m, 2H); LCMS (ESI) m / z: 379.1 [M+H]+.

[0410] Compound 425: 1< H NMR (400 MHz, DMSO-d6) δ 9.48 (brs, 1H), 8.35 (s, 1H), 8.29 (d, J= 6 Hz, 1H), 8.11 (d, J= 8.4 Hz, 1H), 7.78 (dd, J=2 Hz, 8.4 Hz, 1H), 7.29-7.39 (m, 1H),7.08-7.18 (m, 2H), 6.98-7.07 (m, 1H), 6.95 (d, J=6 Hz, 1H), 3.99 (s, 2 H); LCMS (ESI) m / z: 325.1 [M+H]+.

[0411] Compound 427: 1< H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H), 8.65 (d, J = 2.4 Hz, 1H), 8.19 (d, J = 3.2 Hz, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.98 (dd, J = 9.2, 2.4 Hz, 1H), 7.86 (dd, J = 8.8, 2.4 Hz, 1H), 7.83 (s, 1H), 7.73 (d, J = 10.0 Hz, 1H), 7.57 (dd, J = 8.8, 2.8 Hz, 1H), 6.43 (d, J = 9.6 Hz, 1H), 5.25 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m / z: 379.0 [M+H]+.

[0412] Compound 441: 1< H NMR (400 MHz, TFA) δ 8.80 (d, J = 4.4 Hz, 1H), 8.78 (d, J = 4.8 Hz, 1H), 8.74 (d, J = 2.8 Hz, 1H), 8.42 (d, J = 9.6 Hz, 1H), 8.22 (s, 1H), 8.07 (d, J = 8.0 Hz, 1H), 8.00 (t, J = 9.2 Hz, 2H), 5.85 (s, 2H), 4.58 (s, 3H); LCMS (ESI) m / z: 380.0 [M+H]+.

[0413] Compound 452: 1< H NMR (500 MHz, DMSO-d6) δ 10.63 (s, 1H), 8.69 (d, J = 2.7 Hz, 1H), 8.45 (d, J = 2.3 Hz, 1H), 8.16 (d, J = 8.6 Hz, 1H), 7.99 (dd, J = 9.5, 2.7 Hz, 1H), 7.90 (dd, J = 8.6, 2.4 Hz, 1H), 7.20 - 7.10 (m, 2H), 7.08 - 7.00 (m, 2H), 6.44 (d, J = 9.5 Hz, 1H), 5.08 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m / z: 354.1 [M+H]+.Example 239. Characterization Data of Compounds of the Invention

[0414] The following compounds were synthesized by methods similar to those described above. CMPD No. Characterization Data 480 LCMS (ESI) m / z: 341.2[M+H] +< . 1< H NMR (500 MHz, CDCl 3 ) δ 8.40(s, 1H), 8.21 - 8.11 (m, 2H), 7.54 (dd, J = 8.5, 2.2 Hz, 1H), 7.05 - 6.83 (m, 4H), 5.57-5.52 (m, 1H), 4.14 (d, J = 4 Hz, 2H), 3.97 (s, 2H), 2.97 (s, 3H).515 LCMS (ESI) m / z: 356.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.94 (s, 1H), 8.33 (s, 1H), 8.04 (s, 1H), 7.77 (d, J = 40.6 Hz, 2H), 7.37 (s, 2H), 7.03 (d, J = 68.1 Hz, 2H), 6.61 (s, 1H), 3.96 (s, 2H), 3.40 (s, 3H).523 LCMS (ESI) m / z: 371.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.02 (s, 1H), 8.33 (d, J = 1.8 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 1.2 Hz, 1H), 7.75 (dd, J = 8.5, 2.4 Hz, 1H), 7.36 - 7.33 (m, 2H), 7.12 (s, 1H), 3.96 (s, 2H), 3.79 (s, 3H), 2.17 (d, J = 1.1 Hz, 3H).524 LCMS (ESI) m / z: 371.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.07 (s, 1H), 8.35 (d, J = 4.0 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.89 (d, J = 1.2 Hz, 1H), 7.78 (dd, J = 8.5, 2.4 Hz, 1H), 7.14 - 6.96 (m, 3H), 3.99 (s, 2H), 3.80 (s, 3H), 2.17 (d, J = 1.1 Hz, 3H).531 LCMS (ESI) m / z: 367.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.07 (s, 1H), 8.33 (d, J = 1.9 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.79 (s, 1H), 7.76 (dd, J = 8.5, 2.3 Hz, 1H), 7.38 - 7.35 (m, 1H), 7.21 - 7.09 (m, 2H), 7.08 - 7.03 (m, 1H), 3.99 (s, 2H), 3.80 (s, 3H), 2.57 - 2.53 (m, 2H), 1.16 (t, J = 7.4 Hz, 3H).532 LCMS (ESI) m / z: 357.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 12.15 (s, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.22 (dt, J = 14.0, 6.4 Hz, 3H), 7.78 (dd, J = 8.5, 2.3 Hz, 1H), 7.13 - 7.00 (m, 3H), 3.99 (s, 2H), 3.84 (s, 3H).533 LCMS (ESI) m / z: 356.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.94 (s, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.81 (d, J = 7.0 Hz, 1H), 7.75 (dd, J = 8.5, 2.3 Hz, 1H), 7.14 - 7.00 (m, 3H), 6.95 (d, J = 1.7 Hz, 1H), 6.61 (dd, J = 7.0, 1.9 Hz, 1H), 3.99 (s, 2H), 3.47 (s, 3H).546 LCMS (ESI) m / z: 339.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 12.12 (s, 1H), 8.33 (d, J = 1.9 Hz, 1H), 8.25 - 8.20 (m, 2H), 8.18 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.2 Hz, 1H), 7.35 (dd, J = 14.3, 8.0 Hz, 1H), 7.16 - 7.08 (m, 2H), 7.04 (td, J = 8.6, 2.3 Hz, 1H), 3.98 (s, 2H), 3.83 (s, 3H).547 LCMS (ESI) m / z: 357.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 12.13 (s, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.22 (q, J = 4.3 Hz, 2H), 8.18 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.2 Hz, 1H), 7.42 - 7.29 (m, 2H), 7.15 - 7.07 (m, 1H), 3.96 (s, 2H), 3.84 (s, 3H).548 LCMS (ESI) m / z: 357.1[M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.15 (s, 1H), 8.54 (d, J = 6.5 Hz, 1H), 8.36 (d, J = 1.9 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.78 (dd, J = 8.5, 2.3 Hz, 1H), 7.46-7.29 (m, 2H), 7.17-7.08 (m, 1H), 7.04 (d, J = 6.5 Hz, 1H), 3.97 (s, 2H), 3.54 (s, 3H).550 LCMS (ESI) m / z: 363.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.54 (s, 1H), 8.66 (d, J = 2.6 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.98 (dd, J = 9.5, 2.7 Hz, 1H), 7.88 (dd, J = 6.3, 2.2 Hz, 1H), 7.70 (dd, J = 8.0, 2.2 Hz, 2H), 7.47 (t, J = 8.0 Hz, 1H), 6.43 (d, J = 9.0 Hz, 1H), 4.00 (s, 2H), 3.50 (s, 3H).564 LCMS (ESI) m / z: 364.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.13 (s, 1H), 8.35 (s, 1H), 8.08 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 9.6 Hz, 1H), 7.89 (d, J = 4.7 Hz, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.70 (s, 1H), 7.47 (t, J = 9.0 Hz, 1H), 7.08 (d, J = 9.6 Hz, 1H), 4.02 (s, 2H), 3.79 (s, 3H).582 LCMS (ESI) m / z: 370.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.63 (s, 1H), 8.64 (d, J = 2.6 Hz, 1H), 8.31 (d, J = 1.9 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.94 (dd, J = 9.5, 2.7 Hz, 1H), 7.69 (dd, J = 8.6, 2.4 Hz, 1H), 7.44 - 7.30 (m, 2H), 7.19 - 7.00 (m, 1H), 6.43 (d, J = 9.5 Hz, 1H), 3.97 (dd, J = 13.4, 6.2 Hz, 4H), 1.27 (t, J = 7.1 Hz, 3H).583 LCMS (ESI) m / z: 370.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.64 (s, 1H), 8.65 (d, J = 2.6 Hz, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.94 (dd, J = 9.5, 2.7 Hz, 1H), 7.72 (dd, J = 8.6, 2.4 Hz, 1H), 7.06 (dd, J = 12.9, 4.5 Hz, 3H), 6.43 (d, J = 9.5 Hz, 1H), 4.05 - 3.91 (m, 4H), 1.28 (t, J = 7.1 Hz, 3H).584 LCMS (ESI) m / z: 337.3 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.23 (s, 1H), 8.48 (t, J = 9.8 Hz, 1H), 8.19 (d, J = 8.6 Hz, 1H), 8.08 - 7.85 (m, 2H), 7.45 - 7.20 (m, 2H), 7.14 - 6.88 (m, 4H), 5.12 (s, 2H), 3.80 (s, 3H).590 LCMS (ESI) m / z: 357.1[M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.16 (s, 1H), 8.55 (d, J = 6.5 Hz, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 7.81 (dd, J = 8.5, 2.3 Hz, 1H), 7.16 - 6.93 (m, 4H), 4.00 (s, 2H), 3.54 (s, 3H).596 LCMS (ESI) m / z: 387.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.06 (s, 1H), 8.36 (s, 1H), 8.10 (d, J = 8.5 Hz, 1H), 7.79 (dd, J = 8.0, 2.1 Hz, 1H), 7.26 (s, 1H), 7.06 - 7.03 (m, 3H), 3.99 (s, 2H), 3.93 (s, 3H), 3.78 (s, 3H).599 LCMS (ESI) m / z: 355.3 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 )) δ 10.23 (s, 1H), 8.48 (d, J = 1.9 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H), 7.97 (dd, J = 9.1, 3.3 Hz, 2H), 7.35 - 6.85 (m, 5H), 5.10 (s, 2H), 3.80 (s, 3H).600 LCMS (ESI) m / z: 336.2 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.64 (s, 1H), 8.69 (d, J = 2.1 Hz, 1H), 8.47 (s, 1H), 8.16 (d, J = 8.6 Hz, 1H), 8.06 - 7.79 (m, 2H), 7.31 (t, J = 7.8 Hz, 2H), 7.16 - 6.89 (m, 3H), 6.44 (d, J = 9.5 Hz, 1H), 5.11 (s, 2H), 3.51 (s, 3H).609 LCMS (ESI) m / z: 378.1 [M+H] +< . 1< H NMR (400 MHz,DMSO-d 6 ) δ 10.05 (s, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.88 (s, 1H), 7.79 (dd, J = 8.0, 2.3 Hz, 1H), 7.70 - 7.68 (m, 2H), 7.58 (d, J = 9.9 Hz, 1H), 4.05 (s, 2H), 3.79 (s, 3H), 2.17 (s, 3H).610 LCMS (ESI) m / z: 378.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.04 (s, 1H), 8.34 (s, 1H), 8.08 (d, J = 8.5 Hz, 1H), 7.88 - 7.85 (m, 2H), 7.76 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 4.02 (s, 2H), 3.79 (s, 3H), 2.17 (s, 3H).618 LCMS (ESI) m / z: 379.0 / 381.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.56(s, 1H), 8.67(d, J = 2.4 Hz, 1H), 8.35(d, J = 2.0 Hz, 1H), 8.06(d, J = 8.4 Hz, 1H), 7.97(dd, J 1 = 2.4 Hz, J 2 = 9.6 Hz, 1H), 7.90(t, J = 1.6 Hz, 1H), 7.80(t, J = 1.6 Hz, 1H), 7.77-7.72(m, 2H), 6.43(d, J = 9.6 Hz, 1H), 4.01 (s, 2H), 3.49(s, 3H);620 LCMS (ESI) m / z: 363.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.94 (s, 1H), 8.38 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.81 (d, J = 7.0 Hz, 1H), 7.77 (dd, J = 8.5, 2.3 Hz, 1H), 7.74 - 7.64 (m, 2H), 7.58 (d, J = 9.8 Hz, 1H), 6.94 (d, J = 1.8 Hz, 1H), 6.61 (dd, J = 7.0, 2.0 Hz, 1H), 4.05 (s, 2H), 3.46 (s, 3H).623 LCMS (ESI) m / z: 352.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.46 (s, 1H), 8.55 (d, J = 2.5 Hz, 1H), 8.30 (d, J = 2.1 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.93 - 7.88 (m, 1H), 7.69 (dd, J = 8.6, 2.4 Hz, 1H), 7.30-7.36 (m, 1H), 7.10-7.16 (m, 2H), 6.95-7.08 (m, 1H), 3.97 (s, 2H), 3.51 (s, 3H), 2.05 (s, 3H).624 LCMS (ESI) m / z: 353.1[M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 8.33 (d, J = 2.0 Hz, 1H), 8.21 - 8.14 (m, 2H), 7.75 (dd, J = 8.5, 2.3 Hz, 1H), 7.35 (td, J = 8.0, 6.3 Hz, 1H), 7.15 - 7.08 (m, 2H), 7.03 (td, J = 8.4, 2.3 Hz, 1H), 3.98 (s, 2H), 3.78 (s, 3H), 2.40 (s, 3H).626 LCMS (ESI) m / z: 380.0 / 382.0 [M+H] +< . 1< H NMR (400 MHz, CDCl 3 ) δ 9.47(s, 1H), 8.30(d, J = 8.8 Hz, 1H), 8.20(s, 1H), 8.05(d, J = 9.6 Hz, 1H), 7.55-7.52(m, 2H), 7.40(s, 1H), 7.36(s, 1H), 7.04(d, J = 10.0 Hz, 1H), 3.99 (s, 2H), 3.89(s, 3H);647 LCMS (ESI) m / z: 382.0[M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.56 (s, 1H), 8.67 (d, J = 2.5 Hz, 1H), 8.26 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.6 Hz, 1H), 7.98 (dd, J = 9.5, 2.5 Hz, 1H), 7.73 (dd, J = 8.7, 2.4 Hz, 1H), 7.44 - 7.24 (m, 2H), 7.09 (brs, 1H), 6.43 (d, J = 9.5 Hz, 1H), 3.50 (s, 3H), 1.31 (s, 4H).652 LCMS (ESI) m / z: 355.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.73 (s, 1H), 9.06 (d, J = 3.3 Hz, 1H), 8.99 (d, J = 3.3 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.71 (dd, J = 8.6, 2.4 Hz, 1H), 7.39 - 7.31 (m, 2H), 7.27 (ddd, J = 13.7, 7.8, 4.3 Hz, 2H), 3.97 (s, 2H), 3.51 (s, 3H).653 LCMS (ESI) m / z: 383.1[M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.15 (s, 1H), 8.29 (d, J = 2.1 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.95 (d, J = 9.7 Hz, 1H), 7.79 (dd, J = 8.6, 2.4 Hz, 1H), 7.39 - 7.28 (m, 2H), 7.05-7.12 (m, 2H), 3.79 (s, 3H), 1.32 (s, 4H).658 LCMS (ESI) m / z: 373.0 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.26 (s, 1H), 8.50 (d, J = 2.1 Hz, 1H), 8.20 (d, J = 8.5 Hz, 1H), 8.05 - 7.87 (m, 2H), 7.09 (d, J = 9.7 Hz, 1H), 6.98 - 6.69 (m, 3H), 5.16 (s, 2H), 3.80 (s, 3H).664 LCMS (ESI) m / z: 372.9 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.25 (s, 1H), 8.49 (d, J = 2.1 Hz, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.08 - 7.84 (m, 2H), 7.38 (dd, J = 19.8, 9.4 Hz, 1H), 7.21 (ddd, J = 12.3, 6.6, 2.8 Hz, 1H), 7.09 (d, J = 9.7 Hz, 1H), 6.94 - 6.82 (m, 1H), 5.12 (s, 2H), 3.80 (s, 3H).667 LCMS (ESI) m / z: 388.9 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.24 (s, 1H), 8.50 (s, 1H), 8.20 (d, J = 8.6 Hz, 1H), 8.06 - 7.88 (m, 2H), 7.50 (t, J = 8.9 Hz, 1H), 7.20 (dd, J = 11.4, 2.7 Hz, 1H), 7.09 (d, J = 9.7 Hz, 1H), 6.94 (d, J = 11.4 Hz, 1H), 5.15 (s, 2H), 3.80 (s, 3H).670 LCMS (ESI) m / z: 371.2 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.23 (s, 1H), 8.48 (d, J = 1.8 Hz, 1H), 8.19 (d, J = 8.5 Hz, 1H), 7.97 (dd, J = 9.1, 3.4 Hz, 2H), 7.43 - 7.28 (m, 2H), 7.18 - 6.92 (m, 3H), 5.12 (s, 2H), 3.80 (s, 3H).671 LCMS (ESI) m / z: 396.0[M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.27 (s, 1H), 8.51 (s, 1H), 8.21 (d, J = 8.5 Hz, 1H), 7.98 (t, J = 8.4 Hz, 2H), 7.68 - 7.53 (m, 3H), 7.09 (d, J = 9.6 Hz, 1H), 5.23 (s, 2H), 3.80 (s, 3H).672 LCMS (ESI) m / z: 357.1[M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 9.79 (s, 1H), 8.61 (s, 1H), 8.32 (s, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.05 (s, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.05 (dd, J = 14.7, 8.8 Hz, 3H), 3.98 (s, 2H), 3.55 (s, 3H).673 LCMS (ESI) m / z: 357.1[M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 9.78 (s, 1H), 8.62 (s, 1H), 8.30 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.05 (s, 1H), 7.80 - 7.71 (m, 1H), 7.36 (dd, J = 19.3, 8.6 Hz, 2H), 7.12- 7.04 (m, 1H), 3.95 (s, 2H), 3.55 (s, 3H).676 LCMS (ESI) m / z: 370.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.48 (s, 1H), 8.55 (d, J = 1.9 Hz, 1H), 8.32 (s, 1H), 8.07 (d, J = 8.5 Hz, 1H), 7.91 (s, 1H), 7.72 (dd, J = 8.5, 1.9 Hz, 1H), 7.05 (dd, J = 12.5, 4.6 Hz, 3H), 3.97 (s, 2H), 3.51 (s, 3H), 2.05 (s, 3H).679 LCMS (ESI) m / z: 370.1 [M+H] +< . 1< H NMR (400 MHz, DMSO-d 6 ) δ 10.46 (s, 1H), 8.55 (d, J = 2.2 Hz, 1H), 8.30 (s, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.90 (s, 1H), 7.69 (dd, J = 8.6, 2.1 Hz, 1H), 7.37 (dd, J = 10.6, 8.5 Hz, 2H), 7.12 (s, 1H), 3.94 (s, 2H), 3.51 (s, 3H), 2.05 (s, 3H). Example 240. Stearoyl-CoA desaturase (SCD) is the target of the Compounds of the Invention A. Materials and Methods: Compound Profiling Methods

[0415] Strains expressing SCD1 or SCD5 as the sole desaturase, the human SCD1 and SCD5 genes were used to evaluate inhibition of SCD1 / SCD5 using reduced growth as a surrogate for SCD inhibition. These yeast strains express human SCD1 or SCD5 from a plasmid harbored in a strain in which the yeast OLE1 gene is deleted.

[0416] All compound profiling experiments were performed using the same basic protocol. Yeast were cultured using standard techniques in complete synthetic media lacking uracil and containing yeast nitrogen base supplemented with 2% (w / v) glucose (SD-Ura) Starter cultures wwere inoculated in 3 mL SD-Ura media containing 0.01% tween and 0.2 mM palmitoleic and oleic acid. Cultures were incubated overnight in a 30°C shaker incubator (225 rpm). Saturated morning cultures were centrifuged, washed in SD-Ura media lacking TWEEN-20 and fatty acids, and then diluted 1:20 in fresh SD-Ura media also lacking TWEEN-20 and fatty acids. Cells were grown for 6 h to an OD 600 (optical density) of ~0.4-0.8 at 30°C with shaking.

[0417] Compound stocks (10 mM in 100% DMSO) were arrayed into 384-round well, v-bottom polypropylene plates and diluted according to indicated dilution factors. Compound administration was performed in two separate steps. First, 15 µL of SD-Ura was dispensed into clear 384-well assay plates using a MULTIDROP ™< Combi reagent dispenser. The diluted compound stock plates were then applied to the assay plates using an automated workstation (Perkin Elmer JANUS ™< ) outfitted with a 384-pin tool containing slotted pins that deliver 100 nL of compound. The cultures described above were centrifuged and washed with media lacking TWEEN-20 or oleic and palmitoleic acids. Cultures were then resuspended at a 2-fold concentrated OD600 of 0.02 (final OD 600 of 0.0.01) in SD-Ura. 15 µL of diluted culture was then dispensed into the pinned assay plate to achieve 30 µL of the 1x OD 600 culture (0.01) and a top drug concentration of 33.3 µM.

[0418] After yeast delivery, assay plates were incubated under humidified conditions at 30 °C for 40 h. Yeast growth was monitored by reading the OD 600 of each well using a microplate reader (Perkin Elmer EnVision ™< ). Data were analyzed as follows. Raw data were processed by background subtracting and converting values to a percent of the nontreated condition for that strain [(EXP-0.035) / (DMSO-0.035) x 100%].B. Results

[0419] Using the methods described above, the inhibition of SCD1 and SCD5 was tested for compounds of the invention and reference compounds. The results are shown in Table 3. Table 3. Inhibition of SCD1 and SCD5 by Compounds of the InventionCompound No. SCD1 IC50 (µM) SCD5 IC50 (µM) 25 4.030.5335 >45.000.3036 16.890.3837 10.250.0539 >45.000.9240 0.110.0142 2.410.0843 4.060.2144 14.120.7845 15.390.4346 0.060.0147 1.100.1348 0.150.0150 1.530.0253 0.280.0155 1.210.1659 0.310.0160 4.380.6562 2.342.0663 0.380.3264 0.560.0666 1.440.0167 0.440.1268 1.650.2669 >45.000.2770 2.900.4971 >45.003.9172 4.700.3973 8.080.1774 0.250.0175 1.490.0176 0.010.0177 >45.006.7380 27.881.5781 >45.002.4282 >45.000.0383 >45.000.4284 6.660.3785 3.210.30108 7.611.40117 0.630.07127 3.120.22128 0.180.01140 0.290.01171 >45.000.86172 2.290.37173 1.720.15174 7.560.08240 4.390.31248 0.200.01251 >45.000.15256 0.750.04258 3.860.18262 3.980.26263 >45.000.17264 >45.008.84266 1.850.40272 >45.0012.96273 >45.003.25280 0.130.02282 0.210.02286 4.000.24287 0.860.14291 22.534.91298 2.750.34300 >45.005.60301 >45.005.22302 >45.003.34303 4.180.97304 >45.002.70328 1.760.01329 0.100.01330 0.570.01331 0.130.01332 1.680.48335 15.400.69342 >45.0020.94349 >45.0032.30360 32.566.59361 >45.002.63365 25.814.00367 25.842.98411 >45.00>45.00421 >45.00>45.00425 >45.00>45.00427 >45.00>45.00441 >45.00>45.00452 >45.00>45.00480 3.50.23515 5.90.32523 >45.000.11524 >45.000.029531 1.30.34532 0.010.01533 0.220.01546 0.320.027547 0.240.01548 >45.003550 2.40.37564 1.40.062582 4.30.28583 NTNT584 >45.001.2590 300.47596 1.080.026599 >45.000.94600 281.6609 >45.000.284610 3.40.6618 0.510.022620 0.20.2623 0.2320.019624 >45.000.054626 >45.000.014647 9.32.4652 1.90.086653 >45.001.4658 1.60.18664 310.9667 >45.000.31670 >45.001.8671 >45.002672 0.50.42673 3.10.36676 0.0830.01679 0.570.01"NT" indicates not tested Other Embodiments

[0420] While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover compounds included within the scope of the appended claims.

Claims

1. A compound having the structure of Formula Ic: wherein R1 is phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-di-fluoro-phenyl, 3,4-dichloro-phenyl, 3,5-di-fluoro-phenyl, 3,5-dichloro-phenyl, 3-chloro-4-fluoro-phenyl, 4-chloro-3-fluoro-phenyl, 3-chloro-4-nitrile-phenyl, 3-nitrile-4-fluoro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 3-bromo-phenyl, 3-cyclopropyl-phenyl, 3-cyano-5-fluoro-phenyl, 3-chloro-5-fluoro-phenyl, 3-chloro-5-cyano-phenyl, 3-chloro-5-methoxy-phenyl, or 1,3-dihydroisobenzofuran; L1 is or R2 is wherein e is 0, 1, or 2; each R11 is, independently, F, Cl, Br, I, CN, or W is CH or N; Y is NRY1; RY1 is H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, or optionally substituted C2-C9 heterocyclyl; Z is O, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein L1 is 3. The compound of any one of claims 1 or 2, wherein R2 is 4. The compound of claim 3, wherein R2 is 5. The compound of claim 1, wherein the compound has the following structure: and pharmaceutically acceptable salts thereof.

6. The compound of any one of claims 1 to 5, wherein the compound has the following structure 7. The compound of any one of claims 1 to 6, wherein the compound has the following structure 8. The compound of any one of claims 1 to 7, wherein the compound has the following structure in the form of the free base.

9. The compound of any one of claims 1 to 7, wherein the compound has the following structure in the form of the free base.

10. The compound of any one of claims 1 to 7, wherein the compound has the following structure in the form of the free base.

11. The compound of any one of claims 1 to 7, wherein the compound has the following structure in the form of the free base.

12. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-11, and a pharmaceutically acceptable excipient.

13. A compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use in therapy.

14. A compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use in the treatment of a neurological disorder.

15. A compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use according to claim 14 wherein the neurological disorder is selected from Alexander disease, Alper' s disease, Alzheimer's Disease (AD), amyotrophic lateral sclerosis, ataxia telangiectasia, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, multiple sclerosis, Parkinson's Disease (PD), Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, Ref sum's disease, Sandhoff disease, Schilder' s disease, Steele-Richardson Olszewski disease, tabes dorsalis, and Guillain-Barre Syndrome.

16. A compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use according to claim 15, wherein the neurological disorder is Lewy body dementia.

17. A compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use according to claim 15, wherein the neurological disorder is Parkinson's Disease.

18. A compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use in the inhibition of toxicity in a cell related to a protein, in particular toxicity related to α-synuclein or toxicity related to ApoE4.

19. A compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use in the treatment of a stearoyl-CoA desaturase (SCD)-associated disorder, in particular a SCD5-associated disorder.

20. A compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use in the inhibition of SCD5 or SCD1.

21. A compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1-11, or a pharmaceutical composition of claim 12, for use as defined in claim 19, wherein the SCD-associated disorder is brain cancer.